{ "version": "2.2", "instance": { "nbx-20251231.htm": { "nsprefix": "nbx", "nsuri": "http://nanobiotix.com/20251231", "dts": { "inline": { "local": [ "nbx-20251231.htm" ] }, "schema": { "local": [ "nbx-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "nbx-20251231_cal.xml" ] }, "definitionLink": { "local": [ "nbx-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "nbx-20251231_lab.xml" ] }, "presentationLink": { "local": [ "nbx-20251231_pre.xml" ] } }, "keyStandard": 333, "keyCustom": 219, "axisStandard": 37, "axisCustom": 14, "memberStandard": 48, "memberCustom": 164, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2025": 5, "http://nanobiotix.com/20251231": 2 }, "contextCount": 1013, "entityCount": 1, "segmentCount": 233, "elementCount": 1148, "unitCount": 15, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 2351, "http://xbrl.sec.gov/dei/2025": 50, "http://xbrl.sec.gov/cyd/2025": 14, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://nanobiotix.com/role/Coverpage", "longName": "0000001 - Document - Cover page", "shortName": "Cover page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R2": { "role": "http://nanobiotix.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R3": { "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "longName": "9952151 - Statement - STATEMENTS OF CONSOLIDATED FINANCIAL POSITION", "shortName": "STATEMENTS OF CONSOLIDATED FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:NoncurrentAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R4": { "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS", "longName": "9952152 - Statement - STATEMENTS OF CONSOLIDATED OPERATIONS", "shortName": "STATEMENTS OF CONSOLIDATED OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R5": { "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS", "longName": "9952153 - Statement - STATEMENTS OF CONSOLIDATED COMPREHENSIVE INCOME (LOSS)", "shortName": "STATEMENTS OF CONSOLIDATED COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R6": { "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "longName": "9952154 - Statement - STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS\u2019 EQUITY", "shortName": "STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-14", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R7": { "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS", "longName": "9952155 - Statement - STATEMENTS OF CONSOLIDATED CASH FLOWS", "shortName": "STATEMENTS OF CONSOLIDATED CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R8": { "role": "http://nanobiotix.com/role/Companyinformation", "longName": "9952156 - Disclosure - Company information", "shortName": "Company information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfNotesAndOtherExplanatoryInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfNotesAndOtherExplanatoryInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R9": { "role": "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentation", "longName": "9952157 - Disclosure - General Information, Statement of Compliance and Basis of Presentation", "shortName": "General Information, Statement of Compliance and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R10": { "role": "http://nanobiotix.com/role/Consolidationprinciplesandmethods", "longName": "9952158 - Disclosure - Consolidation principles and methods", "shortName": "Consolidation principles and methods", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R11": { "role": "http://nanobiotix.com/role/Significanttransactions", "longName": "9952159 - Disclosure - Significant transactions", "shortName": "Significant transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfSignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfSignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R12": { "role": "http://nanobiotix.com/role/Intangibleassets", "longName": "9952160 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R13": { "role": "http://nanobiotix.com/role/Propertyplantandequipment", "longName": "9952161 - Disclosure - Property, plant and equipment", "shortName": "Property, plant and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R14": { "role": "http://nanobiotix.com/role/Noncurrentfinancialassets", "longName": "9952162 - Disclosure - Non-current financial assets", "shortName": "Non-current financial assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R15": { "role": "http://nanobiotix.com/role/Tradereceivablesandothercurrentassets", "longName": "9952163 - Disclosure - Trade receivables and other current assets", "shortName": "Trade receivables and other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R16": { "role": "http://nanobiotix.com/role/Cashandcashequivalents", "longName": "9952164 - Disclosure - Cash and cash equivalents", "shortName": "Cash and cash equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R17": { "role": "http://nanobiotix.com/role/Sharecapital", "longName": "9952165 - Disclosure - Share capital", "shortName": "Share capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R18": { "role": "http://nanobiotix.com/role/Retirementobligations", "longName": "9952166 - Disclosure - Retirement obligations", "shortName": "Retirement obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R19": { "role": "http://nanobiotix.com/role/Provisions", "longName": "9952167 - Disclosure - Provisions", "shortName": "Provisions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R20": { "role": "http://nanobiotix.com/role/Financialliabilities", "longName": "9952168 - Disclosure - Financial liabilities", "shortName": "Financial liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfFinancialLiabilitiesFootnoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfFinancialLiabilitiesFootnoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R21": { "role": "http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities", "longName": "9952169 - Disclosure - Trade payables and other current liabilities", "shortName": "Trade payables and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R22": { "role": "http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome", "longName": "9952170 - Disclosure - Financial instruments included in the statement of financial position and impact on income", "shortName": "Financial instruments included in the statement of financial position and impact on income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R23": { "role": "http://nanobiotix.com/role/Revenuesandotherincome", "longName": "9952171 - Disclosure - Revenues and other income", "shortName": "Revenues and other income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R24": { "role": "http://nanobiotix.com/role/Operatingexpenses", "longName": "9952172 - Disclosure - Operating expenses", "shortName": "Operating expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R25": { "role": "http://nanobiotix.com/role/Sharebasedpayments", "longName": "9952173 - Disclosure - Share-based payments", "shortName": "Share-based payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R26": { "role": "http://nanobiotix.com/role/Netfinancialincomeloss", "longName": "9952174 - Disclosure - Net financial income (loss)", "shortName": "Net financial income (loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R27": { "role": "http://nanobiotix.com/role/Incometax", "longName": "9952175 - Disclosure - Income tax", "shortName": "Income tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R28": { "role": "http://nanobiotix.com/role/Segmentreporting", "longName": "9952176 - Disclosure - Segment reporting", "shortName": "Segment reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R29": { "role": "http://nanobiotix.com/role/Losspershare", "longName": "9952177 - Disclosure - Loss per share", "shortName": "Loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R30": { "role": "http://nanobiotix.com/role/Commitments", "longName": "9952178 - Disclosure - Commitments", "shortName": "Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R31": { "role": "http://nanobiotix.com/role/Relatedparties", "longName": "9952179 - Disclosure - Related parties", "shortName": "Related parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R32": { "role": "http://nanobiotix.com/role/Subsequentevents", "longName": "9952180 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R33": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R34": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R35": { "role": "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies", "longName": "9955511 - Disclosure - Consolidation principles and methods (Policies)", "shortName": "Consolidation principles and methods (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R36": { "role": "http://nanobiotix.com/role/IntangibleassetsTables", "longName": "9955512 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R37": { "role": "http://nanobiotix.com/role/PropertyplantandequipmentTables", "longName": "9955513 - Disclosure - Property, plant and equipment (Tables)", "shortName": "Property, plant and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R38": { "role": "http://nanobiotix.com/role/NoncurrentfinancialassetsTables", "longName": "9955514 - Disclosure - Non-current financial assets (Tables)", "shortName": "Non-current financial assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R39": { "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables", "longName": "9955515 - Disclosure - Trade receivables and other current assets (Tables)", "shortName": "Trade receivables and other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R40": { "role": "http://nanobiotix.com/role/CashandcashequivalentsTables", "longName": "9955516 - Disclosure - Cash and cash equivalents (Tables)", "shortName": "Cash and cash equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R41": { "role": "http://nanobiotix.com/role/SharecapitalTables", "longName": "9955517 - Disclosure - Share capital (Tables)", "shortName": "Share capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R42": { "role": "http://nanobiotix.com/role/RetirementobligationsTables", "longName": "9955518 - Disclosure - Retirement obligations (Tables)", "shortName": "Retirement obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R43": { "role": "http://nanobiotix.com/role/ProvisionsTables", "longName": "9955519 - Disclosure - Provisions (Tables)", "shortName": "Provisions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://nanobiotix.com/role/FinancialliabilitiesTables", "longName": "9955520 - Disclosure - Financial liabilities (Tables)", "shortName": "Financial liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nbx:DisclosureOfFinancialLiabilitiesFootnoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R45": { "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables", "longName": "9955521 - Disclosure - Trade payables and other current liabilities (Tables)", "shortName": "Trade payables and other current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R46": { "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables", "longName": "9955522 - Disclosure - Financial instruments included in the statement of financial position and impact on income (Tables)", "shortName": "Financial instruments included in the statement of financial position and impact on income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R47": { "role": "http://nanobiotix.com/role/RevenuesandotherincomeTables", "longName": "9955523 - Disclosure - Revenues and other income (Tables)", "shortName": "Revenues and other income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R48": { "role": "http://nanobiotix.com/role/OperatingexpensesTables", "longName": "9955524 - Disclosure - Operating expenses (Tables)", "shortName": "Operating expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R49": { "role": "http://nanobiotix.com/role/SharebasedpaymentsTables", "longName": "9955525 - Disclosure - Share-based payments (Tables)", "shortName": "Share-based payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R50": { "role": "http://nanobiotix.com/role/NetfinancialincomelossTables", "longName": "9955526 - Disclosure - Net financial income (loss) (Tables)", "shortName": "Net financial income (loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R51": { "role": "http://nanobiotix.com/role/IncometaxTables", "longName": "9955527 - Disclosure - Income tax (Tables)", "shortName": "Income tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R52": { "role": "http://nanobiotix.com/role/LosspershareTables", "longName": "9955528 - Disclosure - Loss per share (Tables)", "shortName": "Loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R53": { "role": "http://nanobiotix.com/role/RelatedpartiesTables", "longName": "9955529 - Disclosure - Related parties (Tables)", "shortName": "Related parties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R54": { "role": "http://nanobiotix.com/role/CompanyinformationDetails", "longName": "9955530 - Disclosure - Company information (Details)", "shortName": "Company information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-49", "name": "nbx:CollaborationAgreementTotalConsideration", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "nbx:DisclosureOfNotesAndOtherExplanatoryInformationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "nbx:CollaborationAgreementAggregateNominalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R55": { "role": "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails", "longName": "9955531 - Disclosure - General Information, Statement of Compliance and Basis of Presentation (Details)", "shortName": "General Information, Statement of Compliance and Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:RetainedEarnings", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R56": { "role": "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails", "longName": "9955532 - Disclosure - Consolidation principles and methods (Details)", "shortName": "Consolidation principles and methods (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:ClosingForeignExchangeRate", "unitRef": "usdollarpereuro", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "ifrs-full:ClosingForeignExchangeRate", "unitRef": "usdollarpereuro", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R57": { "role": "http://nanobiotix.com/role/SignificanttransactionsDetails", "longName": "9955533 - Disclosure - Significant transactions (Details)", "shortName": "Significant transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-102", "name": "nbx:InitialFixedReturnAmountCap", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R58": { "role": "http://nanobiotix.com/role/IntangibleassetsDetails", "longName": "9955534 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R59": { "role": "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "longName": "9955535 - Disclosure - Property, plant and equipment - Additional Information (Details)", "shortName": "Property, plant and equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-149", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-138", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "span", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R60": { "role": "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "longName": "9955536 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)", "shortName": "Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R61": { "role": "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails", "longName": "9955537 - Disclosure - Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details)", "shortName": "Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:NoncurrentFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "ifrs-full:NoncurrentFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R62": { "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails", "longName": "9955538 - Disclosure - Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details)", "shortName": "Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock", "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-220", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R63": { "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "longName": "9955539 - Disclosure - Trade receivables and other current assets - Additional Information (Details)", "shortName": "Trade receivables and other current assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock", "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-216", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R64": { "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails", "longName": "9955540 - Disclosure - Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details)", "shortName": "Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentValueAddedTaxReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R65": { "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails", "longName": "9955541 - Disclosure - Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details)", "shortName": "Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-236", "name": "nbx:ProceedsFromIncomeTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R66": { "role": "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails", "longName": "9955542 - Disclosure - Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details)", "shortName": "Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:Cash", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:Cash", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R67": { "role": "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails", "longName": "9955543 - Disclosure - Cash and cash equivalents - Additional Information (Details)", "shortName": "Cash and cash equivalents - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": null }, "R68": { "role": "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "longName": "9955544 - Disclosure - Share capital - Disclosure of Detail of Share Capital Transactions (Details)", "shortName": "Share capital - Disclosure of Detail of Share Capital Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-246", "name": "ifrs-full:IssueOfEquity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R69": { "role": "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "longName": "9955545 - Disclosure - Share capital - Capital Issued (Details)", "shortName": "Share capital - Capital Issued (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-251", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R70": { "role": "http://nanobiotix.com/role/SharecapitalTreasurySharesDetails", "longName": "9955546 - Disclosure - Share capital - Treasury Shares (Details)", "shortName": "Share capital - Treasury Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-35", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": null }, "R71": { "role": "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "longName": "9955547 - Disclosure - Share capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details)", "shortName": "Share capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-276", "name": "ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R72": { "role": "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails", "longName": "9955548 - Disclosure - Share capital - Founders\u2019 warrants (Details)", "shortName": "Share capital - Founders\u2019 warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-278", "name": "nbx:PatientThresholdAmount", "unitRef": "patient", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-293", "name": "nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R73": { "role": "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails", "longName": "9955549 - Disclosure - Share capital - Warrant Plans (Details)", "shortName": "Share capital - Warrant Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-351", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R74": { "role": "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "longName": "9955550 - Disclosure - Share capital - Stock Option Plans (Details)", "shortName": "Share capital - Stock Option Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ParValuePerShare", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-439", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R75": { "role": "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails", "longName": "9955551 - Disclosure - Share capital - Free Share Plans (Details)", "shortName": "Share capital - Free Share Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-463", "name": "nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R76": { "role": "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails", "longName": "9955552 - Disclosure - Retirement obligations - Disclosure of Changes in Provisions (Details)", "shortName": "Retirement obligations - Disclosure of Changes in Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-466", "name": "ifrs-full:OtherProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-472", "name": "ifrs-full:OtherProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R77": { "role": "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails", "longName": "9955553 - Disclosure - Retirement obligations - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)", "shortName": "Retirement obligations - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-4", "name": "nbx:ActuarialAssumptionOfSocialSecurityContributionRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "nbx:ActuarialAssumptionOfSocialSecurityContributionRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R78": { "role": "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails", "longName": "9955554 - Disclosure - Retirement obligations - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details)", "shortName": "Retirement obligations - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-4", "name": "nbx:ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "nbx:ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R79": { "role": "http://nanobiotix.com/role/RetirementobligationsAdditionalInformationDetails", "longName": "9955555 - Disclosure - Retirement obligations - Additional Information (Details)", "shortName": "Retirement obligations - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": null, "uniqueAnchor": null }, "R80": { "role": "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails", "longName": "9955556 - Disclosure - Retirement obligations - Disclosure of Commitments for Retirement Benefits (Details)", "shortName": "Retirement obligations - Disclosure of Commitments for Retirement Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R81": { "role": "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "longName": "9955557 - Disclosure - Provisions - Disclosure of Changes in Provisions (Details)", "shortName": "Provisions - Disclosure of Changes in Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-485", "name": "ifrs-full:OtherProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfProvisionsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-494", "name": "ifrs-full:OtherProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfProvisionsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R82": { "role": "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails", "longName": "9955558 - Disclosure - Provisions - Additional Information (Details)", "shortName": "Provisions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProvisionUsedOtherProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": null }, "R83": { "role": "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "longName": "9955559 - Disclosure - Financial liabilities - Disclosure of Changes in Financial Liabilities (Details)", "shortName": "Financial liabilities - Disclosure of Changes in Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentFinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:FinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "nbx:DisclosureOfFinancialLiabilitiesFootnoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R84": { "role": "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "longName": "9955560 - Disclosure - Financial liabilities - Disclosure of Changes in Liabilities Arising from Financing Activities (Details)", "shortName": "Financial liabilities - Disclosure of Changes in Liabilities Arising from Financing Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestPaidClassifiedAsFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-533", "name": "ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R85": { "role": "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "longName": "9955561 - Disclosure - Financial liabilities - Additional Information (Details)", "shortName": "Financial liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-583", "name": "ifrs-full:InterestRevenueExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R86": { "role": "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "longName": "9955562 - Disclosure - Financial liabilities - Disclosure of Commercialization Date Sensitivity Analysis (Details)", "shortName": "Financial liabilities - Disclosure of Commercialization Date Sensitivity Analysis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-573", "name": "ifrs-full:NetDebt", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-573", "name": "ifrs-full:NetDebt", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R87": { "role": "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails", "longName": "9955563 - Disclosure - Financial liabilities - Disclosure of Cumulated Net Sales Sensitivity Analysis (Details)", "shortName": "Financial liabilities - Disclosure of Cumulated Net Sales Sensitivity Analysis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-575", "name": "ifrs-full:NetDebt", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-575", "name": "ifrs-full:NetDebt", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R88": { "role": "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails", "longName": "9955564 - Disclosure - Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details)", "shortName": "Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R89": { "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails", "longName": "9955566 - Disclosure - Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details)", "shortName": "Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R90": { "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "longName": "9955567 - Disclosure - Trade payables and other current liabilities - Additional Information (Details)", "shortName": "Trade payables and other current liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-1", "name": "nbx:AdjustmentsForIncreaseDecreaseInAccruedExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:AdjustmentsForIncreaseDecreaseInAccruedExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R91": { "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails", "longName": "9955568 - Disclosure - Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details)", "shortName": "Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentTaxLiabilitiesCurrent", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock", "div", "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentTaxLiabilitiesCurrent", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock", "div", "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R92": { "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofCurrentDeferredIncomeandContractLiabilitiesDetails", "longName": "9955569 - Disclosure - Trade payables and other current liabilities - Disclosure of Current Deferred Income and Contract Liabilities (Details)", "shortName": "Trade payables and other current liabilities - Disclosure of Current Deferred Income and Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R93": { "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofRefundLiabilitiesDetails", "longName": "9955570 - Disclosure - Trade payables and other current liabilities - Disclosure of Refund Liabilities (Details)", "shortName": "Trade payables and other current liabilities - Disclosure of Refund Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:NoncurrentRefundsProvision", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DetailedInformationAboutRefundLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": null }, "R94": { "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails", "longName": "9955571 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details)", "shortName": "Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R95": { "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "longName": "9955572 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Additional Information (Details)", "shortName": "Financial instruments included in the statement of financial position and impact on income - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:BudgetedExchangeRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R96": { "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails", "longName": "9955573 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details)", "shortName": "Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-714", "name": "nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInRoyaltyFinanacingDueToTenPercentIncreaseInExchangeRate", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-714", "name": "nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInRoyaltyFinanacingDueToTenPercentIncreaseInExchangeRate", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R97": { "role": "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "longName": "9955574 - Disclosure - Revenues and other income - Additional Information (Details)", "shortName": "Revenues and other income - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:ResearchTaxCreditUtilizationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R98": { "role": "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails", "longName": "9955575 - Disclosure - Revenues and other income - Schedule of Revenues and Other Income (Details)", "shortName": "Revenues and other income - Schedule of Revenues and Other Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:ResearchAndDevelopmentTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R99": { "role": "http://nanobiotix.com/role/OperatingexpensesDisclosureofResearchandDevelopmentExpenseDetails", "longName": "9955576 - Disclosure - Operating expenses - Disclosure of Research and Development Expense (Details)", "shortName": "Operating expenses - Disclosure of Research and Development Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-1", "name": "nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R100": { "role": "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails", "longName": "9955577 - Disclosure - Operating expenses - Research and Development, Additional Information (Details)", "shortName": "Operating expenses - Research and Development, Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-1", "name": "nbx:IncreaseDecreasePayrollExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-750", "name": "nbx:IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R101": { "role": "http://nanobiotix.com/role/OperatingexpensesDisclosureofSellingGeneralandAdministrativeExpensesDetails", "longName": "9955578 - Disclosure - Operating expenses - Disclosure of Selling, General and Administrative Expenses (Details)", "shortName": "Operating expenses - Disclosure of Selling, General and Administrative Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-1", "name": "nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R102": { "role": "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails", "longName": "9955579 - Disclosure - Operating expenses - Selling, General and Administrative, Additional Information (Details)", "shortName": "Operating expenses - Selling, General and Administrative, Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-5", "name": "nbx:AdvisoryFees", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "nbx:AdvisoryFees", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R103": { "role": "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "longName": "9955580 - Disclosure - Operating expenses - Payroll Costs, Additional Information (Details)", "shortName": "Operating expenses - Payroll Costs, Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-1", "name": "nbx:IncreaseDecreasePayrollExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "nbx:SponsorshipTransitionPayrollExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R104": { "role": "http://nanobiotix.com/role/OperatingexpensesDisclosureofPayrollCostsDetails", "longName": "9955581 - Disclosure - Operating expenses - Disclosure of Payroll Costs (Details)", "shortName": "Operating expenses - Disclosure of Payroll Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:WagesAndSalaries", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:WagesAndSalaries", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R105": { "role": "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails", "longName": "9955582 - Disclosure - Operating expenses - Disclosure of Depreciation, Amortization and Provision Expenses (Details)", "shortName": "Operating expenses - Disclosure of Depreciation, Amortization and Provision Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AmortisationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AmortisationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R106": { "role": "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails", "longName": "9955583 - Disclosure - Operating expenses - Disclosure of Other Operating Income (Expense) (Details)", "shortName": "Operating expenses - Disclosure of Other Operating Income (Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:MiscellaneousOtherOperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfOtherOperatingIncomeExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:MiscellaneousOtherOperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DisclosureOfOtherOperatingIncomeExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R107": { "role": "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "longName": "9955584 - Disclosure - Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Outstanding (Details)", "shortName": "Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-260", "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R108": { "role": "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "longName": "9955585 - Disclosure - Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Outstanding (Details)", "shortName": "Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-410", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-780", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R109": { "role": "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails", "longName": "9955586 - Disclosure - Share-based payments - Additional Information (Details)", "shortName": "Share-based payments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-295", "name": "ifrs-full:ExercisePriceShareOptionsGranted2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": null }, "R110": { "role": "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "longName": "9955587 - Disclosure - Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Founders' Warrants, Warrants, and Free Shares Granted During Period (Details)", "shortName": "Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Founders' Warrants, Warrants, and Free Shares Granted During Period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-277", "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R111": { "role": "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "longName": "9955588 - Disclosure - Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details)", "shortName": "Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-850", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R112": { "role": "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails", "longName": "9955589 - Disclosure - Net financial income (loss) - Disclosure of Net Financial Income (loss) (Details)", "shortName": "Net financial income (loss) - Disclosure of Net Financial Income (loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:DebtRestructuringValuationImpact", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R113": { "role": "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "longName": "9955590 - Disclosure - Net financial income (loss) - Additional Information (Details)", "shortName": "Net financial income (loss) - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-988", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R114": { "role": "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails", "longName": "9955591 - Disclosure - Income tax - Additional Information (Details)", "shortName": "Income tax - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DeferredTaxLiabilityAsset", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DeferredTaxLiabilityAsset", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R115": { "role": "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails", "longName": "9955592 - Disclosure - Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details)", "shortName": "Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R116": { "role": "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails", "longName": "9955593 - Disclosure - Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)", "shortName": "Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R117": { "role": "http://nanobiotix.com/role/LosspershareAdditionalInformationDetails", "longName": "9955594 - Disclosure - Loss per share - Additional Information (Details)", "shortName": "Loss per share - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R118": { "role": "http://nanobiotix.com/role/CommitmentsDetails", "longName": "9955595 - Disclosure - Commitments (Details)", "shortName": "Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-1", "name": "nbx:EIBLoanGuaranteeBySubsidiariesMinimumPercentageOfConsolidatedGrossRevenuesTotalAssetsOrEBITDA", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nbx:CashBalanceThresholdForMandatoryPIKInterestPayment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "unique": true } }, "R119": { "role": "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofSignificantTransactionsDetails", "longName": "9955596 - Disclosure - Related parties - Schedule of Disclosure of Significant Transactions (Details)", "shortName": "Related parties - Schedule of Disclosure of Significant Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R120": { "role": "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails", "longName": "9955597 - Disclosure - Related parties - Schedule of Disclosure of Transactions Between Liabilities and Receivables (Details)", "shortName": "Related parties - Schedule of Disclosure of Transactions Between Liabilities and Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true, "unique": true } }, "R121": { "role": "http://nanobiotix.com/role/SubsequenteventsDetails", "longName": "9955599 - Disclosure - Subsequent events (Details)", "shortName": "Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-49", "name": "nbx:CollaborationAgreementTotalConsideration", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "nbx:DisclosureOfNotesAndOtherExplanatoryInformationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nbx-20251231.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "nbx_A1100StudyMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "A1100StudyMember", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1100 Study", "label": "1100 Study [Member]", "documentation": "1100 Study" } } }, "auth_ref": [] }, "nbx_A2022TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "A2022TaxYearMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Tax Year", "label": "2022 Tax Year [Member]", "documentation": "2022 Tax Year" } } }, "auth_ref": [] }, "nbx_A2023TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "A2023TaxYearMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Tax Year", "label": "2023 Tax Year [Member]", "documentation": "2023 Tax Year" } } }, "auth_ref": [] }, "nbx_A2024TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "A2024TaxYearMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Tax Year", "label": "2024 Tax Year [Member]", "documentation": "2024 Tax Year" } } }, "auth_ref": [] }, "nbx_A2025StockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "A2025StockOptionPlanMember", "presentation": [ "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 Stock Option Plan", "label": "2025 Stock Option Plan [Member]", "documentation": "2025 Stock Option Plan" } } }, "auth_ref": [] }, "nbx_A2025TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "A2025TaxYearMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 Tax Year", "label": "2025 Tax Year [Member]", "documentation": "2025 Tax Year" } } }, "auth_ref": [] }, "nbx_AGA2020Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AGA2020Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA 2020", "label": "AGA 2020 [Member]", "documentation": "AGA 2020" } } }, "auth_ref": [] }, "nbx_AGA2021Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AGA2021Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA 2021", "label": "AGA 2021 [Member]", "documentation": "AGA 2021" } } }, "auth_ref": [] }, "nbx_AGA2022Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AGA2022Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA 2022", "label": "AGA 2022 [Member]", "documentation": "AGA 2022" } } }, "auth_ref": [] }, "nbx_AGA2023Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AGA2023Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA 2023", "label": "AGA 2023 [Member]", "documentation": "AGA 2023 Member" } } }, "auth_ref": [] }, "nbx_AGA2023P1Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AGA2023P1Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA 2023 - P1", "label": "AGA 2023 - P1 [Member]", "documentation": "AGA 2023 - P1 Member" } } }, "auth_ref": [] }, "nbx_AGA2023P2Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AGA2023P2Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA 2023 - P2", "label": "AGA 2023 - P2 [Member]", "documentation": "AGA 2023 - P2 Member" } } }, "auth_ref": [] }, "nbx_AGAMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AGAMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA", "label": "AGA [Member]", "documentation": "AGA" } } }, "auth_ref": [] }, "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring loss before tax", "label": "Accounting profit" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r3", "r4", "r207", "r208" ] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated depreciation of intangible assets", "terseLabel": "Accumulated depreciation of tangible assets", "label": "Accumulated depreciation and amortisation [member]" } } }, "auth_ref": [ "r16", "r512", "r525", "r528", "r529" ] }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated other comprehensive income" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated other comprehensive income [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r544" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Actuarial assumption of discount rates" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r516" ] }, "nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of discount rates if rates decrease by 25%", "label": "Actuarial Assumption Of Discount Rates If Rates Decrease By 25%", "documentation": "Actuarial Assumption Of Discount Rates If Rates Decrease By 25%" } } }, "auth_ref": [] }, "nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of discount rates if rates increase by 25%", "label": "Actuarial Assumption Of Discount Rates If Rates Increase By 25%", "documentation": "Actuarial Assumption Of Discount Rates If Rates Increase By 25%" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRatesMember", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of discount rates", "label": "Actuarial assumption of discount rates [member]" } }, "en": { "role": { "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r517" ] }, "nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Staff turnover", "label": "Actuarial Assumption Of Expected Average Rates Of Staff Turnover", "documentation": "Actuarial Assumption Of Expected Average Rates Of Staff Turnover" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salary increase rate (including inflation)", "label": "Actuarial assumption of expected rates of salary increases" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [domain]; Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r516" ] }, "ifrs-full_ActuarialAssumptionOfRetirementAge2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfRetirementAge2019", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement assumptions", "label": "Actuarial assumption of retirement age" } }, "en": { "role": { "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r516" ] }, "nbx_ActuarialAssumptionOfSocialSecurityContributionRates": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ActuarialAssumptionOfSocialSecurityContributionRates", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Social security contribution rate", "label": "Actuarial Assumption Of Social Security Contribution Rates", "documentation": "Actuarial Assumption Of Social Security Contribution Rates" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionsAxis", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumptions [axis]", "label": "Actuarial assumptions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_ActuarialAssumptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionsDomain", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumptions [domain]", "label": "Actuarial assumptions [domain]" } }, "en": { "role": { "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails": { "parentTag": "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Losses related to change in financial assumptions", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r22" ] }, "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails": { "parentTag": "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains related to experience", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r515" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r448" ] }, "ifrs-full_AdditionalProvisionsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionalProvisionsOtherProvisions", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails", "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Increases", "terseLabel": "Provision for charges", "label": "Additional provisions, other provisions" } }, "en": { "role": { "documentation": "The amount of additional other provisions made. [Refer: Other provisions]" } } }, "auth_ref": [ "r47", "r232" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r54", "r239" ] }, "nbx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillNet": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillNet", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases", "label": "Additions Other Than Through Business Combinations, Intangible Assets Other Than Goodwill, Net", "documentation": "Additions Other Than Through Business Combinations, Intangible Assets Other Than Goodwill, Net" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase in right-of-use assets", "terseLabel": "Increases", "label": "Additions other than through business combinations, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r11", "r214" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r461" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r461" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r461" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r461" ] }, "nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of debt discounting effect", "label": "Adjustment To Debt Financing Related to Estimated Debt Outflows", "documentation": "Adjustment To Debt Financing Related to Estimated Debt Outflows" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInLoansAndAdvances": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInLoansAndAdvances", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for decrease (increase) in loans and advances", "label": "Adjustments for decrease (increase) in loans and advances" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in loans and advances to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Loans and advances; Profit (loss)]" } } }, "auth_ref": [ "r535" ] }, "nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AdjustmentsForDecreaseIncreaseInOtherReceivables", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in other receivables", "verboseLabel": "Decrease in other receivables", "label": "Adjustments For Decrease (Increase) In Other Receivables", "documentation": "Adjustments For Decrease (Increase) In Other Receivables" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for decrease (increase) in prepaid expenses", "label": "Adjustments for decrease (increase) in prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r535" ] }, "nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Receipt of research tax credit receivable", "label": "Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax", "documentation": "Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "(Increase) / Decrease in trade receivables", "label": "Adjustments for decrease (increase) in trade accounts receivable" } } }, "auth_ref": [ "r532" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Adjustments for depreciation and amortisation expense" } } }, "auth_ref": [ "r533" ] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for fair value losses", "label": "Adjustments for fair value losses (gains)" } } }, "auth_ref": [ "r533" ] }, "ifrs-full_AdjustmentsForFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceCosts", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of net debt", "label": "Adjustments for finance costs" } } }, "auth_ref": [ "r534" ] }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal", "label": "Adjustments for gain (loss) on disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax expense", "label": "Adjustments for income tax expense" } } }, "auth_ref": [ "r71" ] }, "nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AdjustmentsForIncreaseDecreaseInAccruedExpenses", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in accrued expenses", "label": "Adjustments For Increase (Decrease) In Accrued Expenses", "documentation": "Adjustments For Increase (Decrease) In Accrued Expenses" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in contract liability", "label": "Adjustments for increase (decrease) in contract liabilities" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r532" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in deferred income and contract liabilities", "label": "Adjustments for increase (decrease) in deferred income including contract liabilities" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r532" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of discounting financial liabilities and amortized cost", "label": "Adjustments for increase (decrease) in derivative financial liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in derivative financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial liabilities; Profit (loss)]" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase / (Decrease) in other current liabilities", "label": "Adjustments for increase (decrease) in other current liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase / (Decrease) in trade and other payables", "label": "Adjustments for increase (decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r535" ] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Adjustments for provisions" } } }, "auth_ref": [ "r533" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Elimination of other non-cash, non-operating income and expenses", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "nbx_AdjustmentsForRefundsProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AdjustmentsForRefundsProvision", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Adjustments for refunds provision", "label": "Adjustments for Refunds Provision", "documentation": "Adjustments for Refunds Provision" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses related to share-based payments", "label": "Adjustments for share-based payments" } } }, "auth_ref": [ "r533" ] }, "ifrs-full_Advances": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Advances", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advances received", "label": "Advances received, representing contract liabilities for performance obligations satisfied at point in time" } }, "en": { "role": { "documentation": "The amount of advances received representing contract liabilities for performance obligations satisfied at a point in time. [Refer: Contract liabilities; Performance obligations satisfied at point in time [member]]" } } }, "auth_ref": [ "r548", "r551" ] }, "nbx_AdvancesReceivedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AdvancesReceivedInterestRate", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advances, interest rate", "label": "Advances Received, Interest Rate", "documentation": "Advances Received, Interest Rate" } } }, "auth_ref": [] }, "nbx_AdvisoryFees": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AdvisoryFees", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Advisory fees", "label": "Advisory Fees", "documentation": "Advisory Fees" } } }, "auth_ref": [] }, "nbx_AggregateNominalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AggregateNominalValue", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate nominal value", "label": "Aggregate Nominal Value", "documentation": "Aggregate Nominal Value" } } }, "auth_ref": [] }, "nbx_AggregateSubscriptionAssumingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AggregateSubscriptionAssumingPrice", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate subscription assuming price", "label": "Aggregate Subscription Assuming Price", "documentation": "Aggregate Subscription Assuming Price" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r506" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r419", "r430", "r440", "r473" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r422", "r433", "r443", "r476" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r507" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r461" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r468" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r423", "r434", "r444", "r468", "r477", "r481", "r489" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r487" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "nbx_AmericanDepositorySharesNASDAQStockMarketMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AmericanDepositorySharesNASDAQStockMarketMember", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "American depositary shares, each representing one ordinary share, nominal value \u20ac0.03 per share", "label": "American Depository Shares, NASDAQ Stock Market [Member]", "documentation": "American Depository Shares, NASDAQ Stock Market" } } }, "auth_ref": [] }, "ifrs-full_AmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationExpense", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization expense of intangible assets", "label": "Amortisation expense" } } }, "auth_ref": [ "r545" ] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": { "parentTag": "nbx_NetAmountsReceivablePayableRelatedPartyTransactions", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Liabilities", "label": "Amounts payable, related party transactions" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r32", "r35", "r226" ] }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsReceivableRelatedPartyTransactions", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": { "parentTag": "nbx_NetAmountsReceivablePayableRelatedPartyTransactions", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables", "label": "Amounts receivable, related party transactions" } }, "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r32", "r35", "r226" ] }, "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AnalysisOfIncomeAndExpenseAbstract", "lang": { "en-us": { "role": { "label": "Analysis of income and expense [abstract]" } } }, "auth_ref": [] }, "nbx_AnnualLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AnnualLeaseExpense", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual lease expense", "label": "Annual Lease Expense", "documentation": "Annual Lease Expense" } } }, "auth_ref": [] }, "nbx_AnnualRoyaltyRepaymentEstimatedFullFinalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AnnualRoyaltyRepaymentEstimatedFullFinalPayment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of full funding received", "label": "Annual Royalty Repayment, Estimated Full Final Payment", "documentation": "Annual Royalty Repayment, Estimated Full Final Payment" } } }, "auth_ref": [] }, "nbx_AnnualRoyaltyRepaymentEstimatedInitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AnnualRoyaltyRepaymentEstimatedInitialPayment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual royalty repayment, estimated initial payment", "label": "Annual Royalty Repayment, Estimated Initial Payment", "documentation": "Annual Royalty Repayment, Estimated Initial Payment" } } }, "auth_ref": [] }, "nbx_AnnualRoyaltyRepaymentEstimatedPartialFinalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AnnualRoyaltyRepaymentEstimatedPartialFinalPayment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of only partial funding received", "label": "Annual Royalty Repayment, Estimated Partial Final Payment", "documentation": "Annual Royalty Repayment, Estimated Partial Final Payment" } } }, "auth_ref": [] }, "nbx_AnnualRoyaltyRepaymentThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AnnualRoyaltyRepaymentThreshold", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual royalty repayment threshold", "label": "Annual Royalty Repayment Threshold", "documentation": "Annual Royalty Repayment Threshold" } } }, "auth_ref": [] }, "nbx_AnnualShortTermLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AnnualShortTermLeaseExpense", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual short term lease expense", "label": "Annual Short Term Lease Expense", "documentation": "Annual Short Term Lease Expense" } } }, "auth_ref": [] }, "nbx_AnnualSubscriptionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AnnualSubscriptionPrice", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual subscription price", "label": "Annual Subscription Price", "documentation": "Annual Subscription Price" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Theoretical tax rate (statutory rate in France)", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r4", "r208" ] }, "nbx_AsiaLicensingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AsiaLicensingAgreementMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Licensing Agreement", "label": "Asia Licensing Agreement [Member]", "documentation": "Asia Licensing Agreement" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r93", "r94", "r95", "r169", "r172", "r279", "r280", "r305" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "At fair value [member]" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r61", "r65", "r83", "r93", "r247", "r278", "r279" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails", "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [axis]", "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r542", "r545" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails", "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function", "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r542", "r545" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://nanobiotix.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r402", "r403", "r426" ] }, "nbx_AuditorInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "AuditorInformationAbstract", "lang": { "en-us": { "role": { "label": "Auditor Information [Abstract]", "documentation": "Auditor Information" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://nanobiotix.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r402", "r403", "r426" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://nanobiotix.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r402", "r403", "r426" ] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageEffectiveTaxRate", "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Average effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r4", "r208" ] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average foreign exchange rate", "label": "Average foreign exchange rate" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r545" ] }, "ifrs-full_AverageNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageNumberOfEmployees", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofPayrollCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average headcount (employee)", "label": "Average number of employees" } }, "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } } }, "auth_ref": [ "r545" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r484" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r485" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r480" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r480" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r480" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r480" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r480" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r480" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r483" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r482" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r481" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r481" ] }, "nbx_BPIFranceAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BPIFranceAdvanceMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Bpifrance advance", "label": "BPI France Advance [Member]", "documentation": "BPI France Advance" } } }, "auth_ref": [] }, "nbx_BPIFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BPIFranceMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bpifrance", "label": "BPI France [Member]", "documentation": "BPI France" } } }, "auth_ref": [] }, "nbx_BSA2013Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA2013Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2013", "label": "BSA 2013 [Member]", "documentation": "BSA 2013" } } }, "auth_ref": [] }, "nbx_BSA2014Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA2014Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2014", "label": "BSA 2014 [Member]", "documentation": "BSA 2014" } } }, "auth_ref": [] }, "nbx_BSA20151Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA20151Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2015-1", "label": "BSA 2015-1 [Member]", "documentation": "BSA 2015-1" } } }, "auth_ref": [] }, "nbx_BSA20152Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA20152Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2015-2 a", "label": "BSA 2015-2 [Member]", "documentation": "BSA 2015-2" } } }, "auth_ref": [] }, "nbx_BSA20181Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA20181Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2018-1", "label": "BSA 2018-1 [Member]", "documentation": "BSA 2018-1" } } }, "auth_ref": [] }, "nbx_BSA20182Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA20182Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2018-2", "label": "BSA 2018-2 [Member]", "documentation": "BSA 2018-2" } } }, "auth_ref": [] }, "nbx_BSA2018Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA2018Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2018", "label": "BSA 2018 [Member]", "documentation": "BSA 2018 Member" } } }, "auth_ref": [] }, "nbx_BSA20191Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA20191Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2019-1", "label": "BSA 2019-1 [Member]", "documentation": "BSA 2019-1" } } }, "auth_ref": [] }, "nbx_BSA2020Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA2020Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2020", "label": "BSA 2020 [Member]", "documentation": "BSA 2020" } } }, "auth_ref": [] }, "nbx_BSA2021AMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSA2021AMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2021", "label": "BSA 2021 A [Member]", "documentation": "BSA 2021 A" } } }, "auth_ref": [] }, "nbx_BSAMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSAMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA", "label": "BSA [Member]", "documentation": "BSA" } } }, "auth_ref": [] }, "nbx_BSPCE092014Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE092014Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 09-2014", "label": "BSPCE 09-2014 [Member]", "documentation": "BSPCE 09-2014" } } }, "auth_ref": [] }, "nbx_BSPCE20151Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE20151Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 2015-1", "label": "BSPCE 2015-1 [Member]", "documentation": "BSPCE 2015-1" } } }, "auth_ref": [] }, "nbx_BSPCE20153Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE20153Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 2015-3", "label": "BSPCE 2015-3 [Member]", "documentation": "BSPCE 2015-3" } } }, "auth_ref": [] }, "nbx_BSPCE2016Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE2016Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 2016", "label": "BSPCE 2016 [Member]", "documentation": "BSPCE 2016" } } }, "auth_ref": [] }, "nbx_BSPCE2016OrdinaryMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE2016OrdinaryMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 2016 Ordinary", "label": "BSPCE 2016 Ordinary [Member]", "documentation": "BSPCE 2016 Ordinary" } } }, "auth_ref": [] }, "nbx_BSPCE2016PerformanceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE2016PerformanceMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 2016 Performance", "label": "BSPCE 2016 Performance [Member]", "documentation": "BSPCE 2016 Performance" } } }, "auth_ref": [] }, "nbx_BSPCE2017Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE2017Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 2017", "label": "BSPCE 2017 [Member]", "documentation": "BSPCE 2017" } } }, "auth_ref": [] }, "nbx_BSPCE2017OrdinaryMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE2017OrdinaryMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 2017 Ordinary", "label": "BSPCE 2017 Ordinary [Member]", "documentation": "BSPCE 2017 Ordinary" } } }, "auth_ref": [] }, "nbx_BSPCE2017PerformanceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE2017PerformanceMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 2017 P", "label": "BSPCE 2017 Performance [Member]", "documentation": "BSPCE 2017 Performance" } } }, "auth_ref": [] }, "nbx_BSPCE2017ProjectMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCE2017ProjectMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE 2017 P", "label": "BSPCE 2017 Project [Member]", "documentation": "BSPCE 2017 Project" } } }, "auth_ref": [] }, "nbx_BSPCEMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BSPCEMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSPCE", "label": "BSPCE [Member]", "documentation": "BSPCE" } } }, "auth_ref": [] }, "ifrs-full_BankBorrowingsUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BankBorrowingsUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Bank borrowings, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r366", "r375" ] }, "nbx_BanquePubliqueDInvestissementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BanquePubliqueDInvestissementMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Banque Publique d\u2019Investissement", "label": "Banque Publique d\u2019Investissement [Member]", "documentation": "Banque Publique d\u2019Investissement" } } }, "auth_ref": [] }, "nbx_BasedCumulatedNetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BasedCumulatedNetSalesMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base cumulated net sales", "label": "Based Cumulated Net Sales [Member]", "documentation": "Based Cumulated Net Sales" } } }, "auth_ref": [] }, "nbx_BasedDateMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BasedDateMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base date", "label": "Based Date [Member]", "documentation": "Based Date" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Basic loss per share (in euro per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r42", "r43" ] }, "nbx_BorrowingDefermentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingDefermentPeriod", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, deferment period", "label": "Borrowing, Deferment Period", "documentation": "Borrowing, Deferment Period" } } }, "auth_ref": [] }, "nbx_BorrowingGuaranteeFee": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingGuaranteeFee", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, guarantee fee", "label": "Borrowing, Guarantee Fee", "documentation": "Borrowing, Guarantee Fee" } } }, "auth_ref": [] }, "nbx_BorrowingMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingMaturityTerm", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, maturity", "label": "Borrowing, Maturity Term", "documentation": "Borrowing, Maturity Term" } } }, "auth_ref": [] }, "nbx_BorrowingNumberOfPGE": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingNumberOfPGE", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, number of PGE", "label": "Borrowing, Number Of PGE", "documentation": "Borrowing, Number Of PGE" } } }, "auth_ref": [] }, "nbx_BorrowingNumberOfQuarterlyInstalments": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingNumberOfQuarterlyInstalments", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of quarterly instalments", "label": "Borrowing, Number Of Quarterly Instalments", "documentation": "Borrowing, Number Of Quarterly Instalments" } } }, "auth_ref": [] }, "nbx_BorrowingPercentageOfStateGuaranteedLoan": { "xbrltype": "pureItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingPercentageOfStateGuaranteedLoan", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of state-guaranteed loan", "label": "Borrowing, Percentage Of State-Guaranteed Loan", "documentation": "Borrowing, Percentage Of State-Guaranteed Loan" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r548" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r540" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name", "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r540" ] }, "nbx_BorrowingsCumulativeMilestonePrepaymentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingsCumulativeMilestonePrepaymentAmount", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, cumulative milestone prepayment amount", "label": "Borrowings, Cumulative Milestone Prepayment Amount", "documentation": "Borrowings, Cumulative Milestone Prepayment Amount" } } }, "auth_ref": [] }, "nbx_BorrowingsEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingsEffectiveInterestRate", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings effective interest rate", "label": "Borrowings Effective Interest Rate", "documentation": "Borrowings Effective Interest Rate" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r540" ] }, "nbx_BorrowingsMilestonePaymentContigency": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingsMilestonePaymentContigency", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "label": "Borrowings, Milestone Payment Contigency", "documentation": "Borrowings, Milestone Payment Contigency" } } }, "auth_ref": [] }, "nbx_BorrowingsMilestonePaymentFirstInstallmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingsMilestonePaymentFirstInstallmentPeriod", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First installment period", "label": "Borrowings, Milestone Payment, First Installment Period", "documentation": "Borrowings, Milestone Payment, First Installment Period" } } }, "auth_ref": [] }, "nbx_BorrowingsMilestonePaymentSecondInstallmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingsMilestonePaymentSecondInstallmentPeriod", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second installment period", "label": "Borrowings, Milestone Payment, Second Installment Period", "documentation": "Borrowings, Milestone Payment, Second Installment Period" } } }, "auth_ref": [] }, "nbx_BorrowingsNetSalesThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingsNetSalesThreshold", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales threshold", "label": "Borrowings, Net Sales Threshold", "documentation": "Borrowings, Net Sales Threshold" } } }, "auth_ref": [] }, "nbx_BorrowingsProratedPaymentMaximumPercentageOfMilestonePayment": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingsProratedPaymentMaximumPercentageOfMilestonePayment", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prorated payment, maximum percentage of milestone payment", "label": "Borrowings, Prorated Payment, Maximum Percentage Of Milestone Payment", "documentation": "Borrowings, Prorated Payment, Maximum Percentage Of Milestone Payment" } } }, "auth_ref": [] }, "nbx_BorrowingsRemainingNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingsRemainingNotionalAmount", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining notional amount", "label": "Borrowings, Remaining Notional Amount", "documentation": "Borrowings, Remaining Notional Amount" } } }, "auth_ref": [] }, "nbx_BorrowingsWeightedAverageCostOfCapital": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BorrowingsWeightedAverageCostOfCapital", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average cost of capital", "label": "Borrowings, Weighted Average Cost Of Capital", "documentation": "Borrowings, Weighted Average Cost Of Capital" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of Range", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r73", "r97", "r109", "r125", "r201", "r352", "r353", "r540" ] }, "nbx_BpifrancePGEMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BpifrancePGEMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bpifrance \u201cPGE\u201d", "label": "Bpifrance PGE [Member]", "documentation": "Bpifrance PGE" } } }, "auth_ref": [] }, "nbx_BudgetedExchangeRate": { "xbrltype": "pureItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "BudgetedExchangeRate", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of derivative financial instruments", "label": "Budgeted Exchange Rate", "documentation": "Budgeted Exchange Rate" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r403", "r426" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails", "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r10", "r14", "r53", "r57", "r62", "r63", "r64", "r65", "r66", "r131", "r145", "r146", "r213", "r216", "r238", "r241", "r244", "r245", "r246", "r247", "r248", "r259", "r273", "r274" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails", "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount [member]", "label": "Carrying amount [member]" } } }, "auth_ref": [ "r14", "r57", "r62", "r64", "r65", "r131", "r145", "r146", "r216", "r241", "r244", "r246", "r247", "r259", "r273", "r274" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and bank accounts", "label": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r537" ] }, "ifrs-full_CashAdvancesAndLoansMadeToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAdvancesAndLoansMadeToRelatedParties", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": { "parentTag": "nbx_NetCollectionsPaymentsFromRelatedParty", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments", "negatedTerseLabel": "Payments", "label": "Cash advances and loans made to related parties" } }, "en": { "role": { "documentation": "The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r530" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 }, "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Net cash and cash equivalents at beginning of period", "periodEndLabel": "Net cash and cash equivalents at end of period", "totalLabel": "Net cash and cash equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r74", "r91", "r202", "r301" ] }, "nbx_CashAndCashEquivalents1Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CashAndCashEquivalents1Member", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash And Cash Equivalents 1 [Member]", "documentation": "Cash And Cash Equivalents 1" } } }, "auth_ref": [] }, "nbx_CashBalanceThresholdForMandatoryPIKInterestPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CashBalanceThresholdForMandatoryPIKInterestPayment", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash balance threshold for mandatory pik interest payment", "label": "Cash Balance Threshold For Mandatory PIK Interest Payment", "documentation": "Cash Balance Threshold For Mandatory PIK Interest Payment" } } }, "auth_ref": [] }, "nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS_1": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 }, "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow from (used in) operating activities after tax and before change in working capital requirement", "label": "Cash Flow From Operating Activities After Tax And Before Change In Working Capital Requirement", "documentation": "Cash Flow From Operating Activities After Tax And Before Change In Working Capital Requirement" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows from (used in) financing activities", "terseLabel": "Cash flows from financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r67", "r76" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from (used in) financing activities", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows from (used in) investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r67", "r76" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from (used in) investing activities", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "nbx_CashFlowsFromUsedInNonFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CashFlowsFromUsedInNonFinancingActivities", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash from financing activities", "label": "Cash Flows From (Used In) Non Financing Activities", "documentation": "Cash Flows From (Used In) Non Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows from (used in) operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r67", "r76" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from (used in) operating activities", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from (used in) operations, before tax and changes in working capital", "label": "Cash flows from (used in) operations before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r349", "r535" ] }, "ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": { "parentTag": "nbx_NetCollectionsPaymentsFromRelatedParty", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Collections", "label": "Cash receipts from repayment of advances and loans made to related parties" } }, "en": { "role": { "documentation": "The cash inflow from repayment to the entity of loans and advances made to related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r530" ] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [axis]", "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r162", "r265" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [domain]", "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r162", "r265" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [axis]", "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r162", "r265" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities", "label": "Categories of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r162", "r265" ] }, "nbx_ChangeInCashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ChangeInCashAndCashEquivalentsAxis", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change In Cash and Cash Equivalents [Axis]", "label": "Change In Cash and Cash Equivalents [Axis]", "documentation": "Change In Cash and Cash Equivalents" } } }, "auth_ref": [] }, "nbx_ChangeInCashAndCashEquivalentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ChangeInCashAndCashEquivalentsDomain", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change In Cash and Cash Equivalents [Domain]", "label": "Change In Cash and Cash Equivalents [Domain]", "documentation": "Change In Cash and Cash Equivalents [Domain]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r459" ] }, "ifrs-full_ChangesInEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInEquity", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in equity", "label": "Increase (decrease) in equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } } }, "auth_ref": [ "r294" ] }, "ifrs-full_ChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInEquityAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in equity", "label": "Changes in equity [abstract]" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r456" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r454" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails", "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [axis]", "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r116", "r155", "r156", "r178", "r179", "r288" ] }, "ifrs-full_ClassesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails", "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [domain]", "label": "Classes of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r116", "r155", "r156", "r178", "r179", "r288" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [axis]", "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r145", "r148", "r150", "r151", "r273", "r276" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [domain]", "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r145", "r148", "r150", "r151", "r273", "r276" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [axis]", "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r155", "r156", "r178", "r179" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities", "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r155", "r156", "r178", "r179" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r58", "r242" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [domain]", "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r58", "r242" ] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities [axis]", "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r96", "r281" ] }, "ifrs-full_ClassesOfLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesDomain", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities", "label": "Classes of liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r96", "r281" ] }, "ifrs-full_ClassesOfOtherProvisionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfOtherProvisionsDomain", "presentation": [ "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails", "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of other provisions [domain]", "label": "Classes of other provisions [domain]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r50", "r235" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r15", "r217" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [domain]", "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r15", "r217" ] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails", "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of other provisions [axis]", "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r50", "r235" ] }, "nbx_ClinicalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ClinicalProductsMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Products", "label": "Clinical Products [Member]", "documentation": "Clinical Products" } } }, "auth_ref": [] }, "nbx_ClinicalStudiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ClinicalStudiesAxis", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Studies [Axis]", "label": "Clinical Studies [Axis]", "documentation": "Clinical Studies" } } }, "auth_ref": [] }, "nbx_ClinicalStudiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ClinicalStudiesDomain", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Studies [Domain]", "label": "Clinical Studies [Domain]", "documentation": "Clinical Studies [Domain]" } } }, "auth_ref": [] }, "nbx_ClinicalTrialAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ClinicalTrialAccruals", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical trial accruals", "label": "Clinical Trial Accruals", "documentation": "Clinical Trial Accruals" } } }, "auth_ref": [] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Closing foreign exchange rate", "label": "Closing foreign exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r545" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r460" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r460" ] }, "nbx_CollaborationAgreementAggregateConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementAggregateConsiderationAmount", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate consideration amount", "label": "Collaboration Agreement, Aggregate Consideration Amount", "documentation": "Collaboration Agreement, Aggregate Consideration Amount" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementAggregateNominalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementAggregateNominalAmount", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate nominal amount", "label": "Collaboration Agreement, Aggregate Nominal Amount", "documentation": "Collaboration Agreement, Aggregate Nominal Amount" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Agreement [Axis]", "label": "Collaboration Agreement [Axis]", "documentation": "Collaboration Agreement" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementCollected": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementCollected", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement, amount collected", "label": "Collaboration Agreement, Collected", "documentation": "Collaboration Agreement, Collected" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Agreement", "label": "Collaboration Agreement [Domain]", "documentation": "Collaboration Agreement" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementEquityInvestmentCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementEquityInvestmentCompensation", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement, equity investment receivable", "label": "Collaboration Agreement, Equity Investment Compensation", "documentation": "Collaboration Agreement, Equity Investment Compensation" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementMaximumNetSales": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementMaximumNetSales", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement, maximum net sales", "label": "Collaboration Agreement, Maximum Net Sales", "documentation": "Collaboration Agreement, Maximum Net Sales" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementPotentialMilestonesPaymentsToBeReceived", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential development and commercial milestones payments", "label": "Collaboration Agreement, Potential Milestones Payments To Be Received", "documentation": "Collaboration Agreement, Potential Milestones Payments To Be Received" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement, compensation per indication", "label": "Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication", "documentation": "Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementRepaymentTerm": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementRepaymentTerm", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment terms tail period expires period", "label": "Collaboration Agreement Repayment Term", "documentation": "Collaboration Agreement Repayment Term" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementSuccessBasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementSuccessBasedPayment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement, success-based payment", "label": "Collaboration Agreement, Success-Based Payment", "documentation": "Collaboration Agreement, Success-Based Payment" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementTotalConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementTotalConsideration", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deal value", "label": "Collaboration Agreement, Total Consideration", "documentation": "Collaboration Agreement, Total Consideration" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementUpfrontPaymentLicenseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementUpfrontPaymentLicenseFee", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement, upfront payment license fee", "label": "Collaboration Agreement, Upfront Payment License Fee", "documentation": "Collaboration Agreement, Upfront Payment License Fee" } } }, "auth_ref": [] }, "nbx_CollaborationAgreementUpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CollaborationAgreementUpfrontPaymentReceived", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment received", "label": "Collaboration Agreement, Upfront Payment Received", "documentation": "Collaboration Agreement, Upfront Payment Received" } } }, "auth_ref": [] }, "nbx_CommercializationDateSensitivityAnalysisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CommercializationDateSensitivityAnalysisTableTextBlock", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Commercialization Date Sensitivity Analysis", "label": "Commercialization Date Sensitivity Analysis [Table Text Block]", "documentation": "Commercialization Date Sensitivity Analysis" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r465" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r464" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r466" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r463" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "http://nanobiotix.com/role/SharecapitalTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r295" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "http://nanobiotix.com/role/SharecapitalTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity", "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r295" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income (loss)", "terseLabel": "Total comprehensive income (loss)", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r79", "r81", "r88", "r230", "r250", "r290", "r320", "r351" ] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Computer software [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r338" ] }, "nbx_ConditionalAdvanceBPIFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ConditionalAdvanceBPIFranceMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Curadigm Bpi advance", "label": "Conditional Advance, BPI France [Member]", "documentation": "Conditional Advance, BPI France" } } }, "auth_ref": [] }, "nbx_ConditionalAdvancesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ConditionalAdvancesMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayable BPI loan advances", "label": "Conditional Advances [Member]", "documentation": "Conditional Advances" } } }, "auth_ref": [] }, "nbx_ConsolidatedForecastedSalesPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ConsolidatedForecastedSalesPeriod", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecasted sales period", "label": "Consolidated Forecasted Sales, Period", "documentation": "Consolidated Forecasted Sales, Period" } } }, "auth_ref": [] }, "nbx_ConstrainedTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ConstrainedTransactionPrice", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Constrained Transaction Price", "label": "Constrained Transaction Price", "documentation": "Constrained Transaction Price" } } }, "auth_ref": [] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tangible assets in progress", "label": "Construction in progress [member]" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r511" ] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Fax Number", "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r403" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing involvement in derecognised financial assets by type of instrument [axis]", "label": "Continuing involvement in derecognised financial assets by type of instrument [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r367" ] }, "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing involvement in derecognised financial assets by type of instrument [domain]", "label": "Continuing involvement in derecognised financial assets by type of instrument [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of instrument' axis if no other member is used." } } }, "auth_ref": [ "r367" ] }, "nbx_ContractNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ContractNameAxis", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract Name [Axis]", "label": "Contract Name [Axis]", "documentation": "Contract Name" } } }, "auth_ref": [] }, "nbx_ContractNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ContractNameDomain", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Name [Domain]", "label": "Contract Name [Domain]", "documentation": "Contract Name [Domain]" } } }, "auth_ref": [] }, "nbx_ContractTerminationIndemnities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ContractTerminationIndemnities", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract termination indemnities", "label": "Contract Termination Indemnities", "documentation": "Contract Termination Indemnities" } } }, "auth_ref": [] }, "ifrs-full_ContractualCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractualCapitalCommitments", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual capital commitments", "label": "Contractual capital commitments" } }, "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } } }, "auth_ref": [ "r545" ] }, "nbx_ContractualCommitmentsCumulativePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ContractualCommitmentsCumulativePayments", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual commitments, cumulative payments", "label": "Contractual Commitments, Cumulative Payments", "documentation": "Contractual Commitments, Cumulative Payments" } } }, "auth_ref": [] }, "nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ContractualCommitmentsMilestonePaymentAnnualIncrease", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment increase", "label": "Contractual Commitments, Milestone Payment, Annual Increase", "documentation": "Contractual Commitments, Milestone Payment, Annual Increase" } } }, "auth_ref": [] }, "nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment upon receipt of clinical study reports", "label": "Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports", "documentation": "Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports" } } }, "auth_ref": [] }, "nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment upon second regulatory approval", "label": "Contractual Commitments, Milestone Payment Upon Second Regulatory Approval", "documentation": "Contractual Commitments, Milestone Payment Upon Second Regulatory Approval" } } }, "auth_ref": [] }, "nbx_ContractualCommitmentsPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ContractualCommitmentsPayment", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Contractual Commitments, Payment", "documentation": "Contractual Commitments, Payment" } } }, "auth_ref": [] }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [axis]", "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r164" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [axis]", "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r164" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "nbx_CumulatedNetSalesSensitivityAnalysisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CumulatedNetSalesSensitivityAnalysisTableTextBlock", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Cumulated Net Sales Sensitivity Analysis", "label": "Cumulated Net Sales Sensitivity Analysis [Table Text Block]", "documentation": "Cumulated Net Sales Sensitivity Analysis" } } }, "auth_ref": [] }, "nbx_CuradigmSASMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CuradigmSASMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Curadigm SAS", "label": "Curadigm SAS [Member]", "documentation": "Curadigm SAS" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [] }, "nbx_CurrencyForwardContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CurrencyForwardContractsMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Forward Contracts", "label": "Currency Forward Contracts [Member]", "documentation": "Currency Forward Contracts" } } }, "auth_ref": [] }, "nbx_CurrencyOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CurrencyOptionsMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Options", "label": "Currency Options [Member]", "documentation": "Currency Options" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency risk", "label": "Currency risk [member]" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r110", "r111", "r112", "r113", "r165" ] }, "ifrs-full_CurrencySwapContractMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrencySwapContractMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency swap contract [member]", "label": "Currency swap contract [member]" } }, "en": { "role": { "documentation": "This member stands for a currency swap contract. [Refer: Swap contract [member]]" } } }, "auth_ref": [ "r545" ] }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses - clinical trials", "label": "Current accrued expenses and other current liabilities" } }, "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_CurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAdvancesToSuppliers", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current advances to suppliers", "label": "Current advances to suppliers" } }, "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } } }, "auth_ref": [ "r545" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r84", "r309", "r351" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofCurrentDeferredIncomeandContractLiabilitiesDetails": { "parentTag": "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities", "weight": 1.0, "order": 2.0 }, "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofCurrentDeferredIncomeandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current contract liabilities", "label": "Current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofCurrentDeferredIncomeandContractLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofCurrentDeferredIncomeandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income and current contract liabilities", "label": "Current deferred income including current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r548", "r551" ] }, "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofCurrentDeferredIncomeandContractLiabilitiesDetails": { "parentTag": "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities", "weight": 1.0, "order": 1.0 }, "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofCurrentDeferredIncomeandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income", "label": "Current deferred income other than current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]" } } }, "auth_ref": [ "r548", "r551" ] }, "ifrs-full_CurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 2.0 }, "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Current financial liabilities", "verboseLabel": "Of which current", "label": "Current financial liabilities" } }, "en": { "role": { "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r140" ] }, "nbx_CurrentFinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CurrentFinancialLiabilitiesMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current financial liabilities", "label": "Current Financial Liabilities [Member]", "documentation": "Current Financial Liabilities" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r86", "r310", "r351" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "nbx_CurrentOtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CurrentOtherProvisionsMember", "presentation": [ "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Current provisions", "label": "Current Other Provisions [Member]", "documentation": "Current Other Provisions" } } }, "auth_ref": [] }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll tax and other payroll liabilities", "label": "Current payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } } }, "auth_ref": [ "r551" ] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r545" ] }, "ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssetsAbstract", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current prepayments and current accrued income other than current contract assets [abstract]", "label": "Current prepayments and current accrued income other than current contract assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Current provisions", "label": "Current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit receivable", "periodStartLabel": "Research tax credit receivable at beginning of period", "periodEndLabel": "Research tax credit receivable at end of period", "label": "Current receivables from taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } } }, "auth_ref": [ "r549" ] }, "nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit", "label": "Current Receivables From Taxes Other Than Income Tax, Income Tax Credit", "documentation": "Current Receivables From Taxes Other Than Income Tax, Income Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_CurrentRefundsProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentRefundsProvision", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofRefundLiabilitiesDetails": { "parentTag": "ifrs-full_RefundsProvision", "weight": 1.0, "order": 1.0 }, "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current refund liabilities", "label": "Current refunds provision" } }, "en": { "role": { "documentation": "The amount of current provision for refunds. [Refer: Refunds provision]" } } }, "auth_ref": [ "r336", "r337" ] }, "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofPayrollCostsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of services", "negatedLabel": "Retirement benefit obligations", "label": "Increase in net defined benefit liability (asset) resulting from current service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r20", "r220" ] }, "ifrs-full_CurrentTaxLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax liabilities", "label": "Current tax liabilities, current" } }, "en": { "role": { "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]" } } }, "auth_ref": [ "r304" ] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r388", "r392", "r394" ] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VAT receivable", "label": "Current value added tax receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r549" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r411", "r500" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r411", "r500" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r413", "r502" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r413", "r502" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r415", "r504" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r413", "r502" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r406", "r495" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r407", "r496" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r407", "r496" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r405", "r494" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r405", "r494" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r405", "r494" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r408", "r497" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r410", "r499" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r410", "r499" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r411", "r500" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r414", "r503" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r412", "r501" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r409", "r498" ] }, "nbx_DealBeforeAugust2023Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DealBeforeAugust2023Member", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofImpactonDebtofSigningaDealthatwillGeneratePIKEarlyPaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deal Before August 2023 [Member]", "label": "Deal Before August 2023 [Member]", "documentation": "Deal Before August 2023" } } }, "auth_ref": [] }, "nbx_DebtDetailsAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtDetailsAxis", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Details [Axis]", "label": "Debt Details [Axis]", "documentation": "Debt Details" } } }, "auth_ref": [] }, "nbx_DebtDetailsDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtDetailsDomain", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Details [Domain]", "label": "Debt Details [Domain]", "documentation": "Debt Details [Domain]" } } }, "auth_ref": [] }, "nbx_DebtInstrumentEstimatedFairMarketValueInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentEstimatedFairMarketValueInterestRate", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, estimated fair market value", "label": "Debt Instrument, Estimated Fair Market Value Interest Rate", "documentation": "Debt Instrument, Estimated Fair Market Value Interest Rate" } } }, "auth_ref": [] }, "nbx_DebtInstrumentFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentFairValue1", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument fair value", "label": "Debt Instrument Fair Value1", "documentation": "Debt Instrument Fair Value1" } } }, "auth_ref": [] }, "nbx_DebtInstrumentMaximumIssuePremium": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentMaximumIssuePremium", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Premium on issuance of debt instruments", "label": "Debt Instrument, Maximum Issue Premium", "documentation": "Debt Instrument, Maximum Issue Premium" } } }, "auth_ref": [] }, "nbx_DebtInstrumentMaximumNumberOfBondsIssuable": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentMaximumNumberOfBondsIssuable", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, bond Issuance threshold", "label": "Debt Instrument, Maximum Number of Bonds Issuable", "documentation": "Debt Instrument, Maximum Number of Bonds Issuable" } } }, "auth_ref": [] }, "nbx_DebtInstrumentMeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentMeasurementAxis", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Measurement [Axis]", "label": "Debt Instrument Measurement [Axis]", "documentation": "Debt Instrument Measurement" } } }, "auth_ref": [] }, "nbx_DebtInstrumentMeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentMeasurementDomain", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Measurement [Domain]", "label": "Debt Instrument Measurement [Domain]", "documentation": "Debt Instrument Measurement [Domain]" } } }, "auth_ref": [] }, "nbx_DebtInstrumentMilestoneAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentMilestoneAxis", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Milestone [Axis]", "label": "Debt Instrument Milestone [Axis]", "documentation": "Debt Instrument Milestone" } } }, "auth_ref": [] }, "nbx_DebtInstrumentMilestoneDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentMilestoneDomain", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Milestone [Domain]", "label": "Debt Instrument Milestone [Domain]", "documentation": "Debt Instrument Milestone [Domain]" } } }, "auth_ref": [] }, "nbx_DebtInstrumentNominalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentNominalAmount", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nominal amount of debt instruments issued", "label": "Debt Instrument, Nominal Amount", "documentation": "Debt Instrument, Nominal Amount" } } }, "auth_ref": [] }, "nbx_DebtInstrumentRoyaltyFinancingTrigger": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentRoyaltyFinancingTrigger", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from component of royalty financing", "label": "Debt Instrument Royalty Financing Trigger", "documentation": "Debt Instrument Royalty Financing Trigger" } } }, "auth_ref": [] }, "nbx_DebtInstrumentSensitivityAnalysisMultiple": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentSensitivityAnalysisMultiple", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument sensitivity analysis, multiple", "label": "Debt Instrument Sensitivity Analysis, Multiple", "documentation": "Debt Instrument Sensitivity Analysis, Multiple" } } }, "auth_ref": [] }, "nbx_DebtInstrumentUnusedBorrowing": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtInstrumentUnusedBorrowing", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of expected future cash in flows", "label": "Debt Instrument, Unused Borrowing", "documentation": "Debt Instrument, Unused Borrowing" } } }, "auth_ref": [] }, "nbx_DebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtIssuanceCosts", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs", "documentation": "Debt Issuance Costs" } } }, "auth_ref": [] }, "nbx_DebtRestructuringValuationImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DebtRestructuringValuationImpact", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net impact of accretion, discounting and catch-up on EIB loan", "label": "Debt Restructuring Valuation Impact", "documentation": "Debt Restructuring, Valuation Impact" } } }, "auth_ref": [] }, "nbx_DecreaseInEmployeeRelatedExpenseDueToCompanyRealignment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DecreaseInEmployeeRelatedExpenseDueToCompanyRealignment", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sponsorship transition amount", "label": "Decrease in Employee Related Expense Due to Company Realignment", "documentation": "Decrease in Employee Related Expense Due to Company Realignment" } } }, "auth_ref": [] }, "ifrs-full_DecreaseThroughDerecognitionFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DecreaseThroughDerecognitionFinancialAssets", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decreases", "label": "Decrease through derecognition, financial assets" } }, "en": { "role": { "documentation": "The decrease in financial assets resulting from derecognition. [Refer: Financial assets]" } } }, "auth_ref": [ "r359", "r361", "r374", "r384", "r386" ] }, "ifrs-full_DeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilityAsset", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred tax asset", "label": "Deferred tax liability (asset)" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r6", "r210" ] }, "nbx_DeferredTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DeferredTaxRate", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax rate (percent)", "label": "Deferred Tax Rate", "documentation": "Deferred Tax Rate" } } }, "auth_ref": [] }, "nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit liability if actuarial assumption of discount rates decrease by 25%", "label": "Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption", "documentation": "Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption" } } }, "auth_ref": [] }, "nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit liability if actuarial assumption of discount rates increase by 25%", "label": "Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption", "documentation": "Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption" } } }, "auth_ref": [] }, "nbx_DefinedBenefitObligationPayablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DefinedBenefitObligationPayablePeriod", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payable, period", "label": "Defined Benefit Obligation, Payable, Period", "documentation": "Defined Benefit Obligation, Payable, Period" } } }, "auth_ref": [] }, "nbx_DepreciationAmortizationAndProvisionExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DepreciationAmortizationAndProvisionExpenses", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total depreciation, amortization and provision expenses", "label": "Depreciation, Amortization And Provision Expenses", "documentation": "Depreciation, Amortization And Provision Expenses" } } }, "auth_ref": [] }, "nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DepreciationAmortizationAndProvisionExpensesExcludingIAS19", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails": { "parentTag": "nbx_DepreciationAmortizationAndProvisionExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total depreciation, amortization and provision expenses (except IAS 19)", "label": "Depreciation, Amortization And Provision Expenses Excluding IAS 19", "documentation": "Depreciation, Amortization And Provision Expenses Excluding IAS 19" } } }, "auth_ref": [] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization expense of tangible assets", "label": "Depreciation expense" } } }, "auth_ref": [ "r545" ] }, "ifrs-full_DerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialAssets", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative financial assets", "label": "Derivative financial assets" } }, "en": { "role": { "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_DerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative financial liabilities", "label": "Derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r548" ] }, "nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of consolidation", "label": "Description Of Accounting Policy For Basis Of Consolidation [Policy Text Block]", "documentation": "Description Of Accounting Policy For Basis Of Consolidation" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share", "label": "Description of accounting policy for earnings per share [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r546" ] }, "nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent events", "label": "Description Of Accounting Policy For Events After Reporting Period [Policy Text Block]", "documentation": "Description Of Accounting Policy For Events After Reporting Period" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting policies", "label": "Description of accounting policy for financial instruments [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Description of accounting policy for intangible assets other than goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Capital issued", "label": "Description of accounting policy for issued capital [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Description of accounting policy for provisions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue and other income", "label": "Description of accounting policy for recognition of revenue [text block]" } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment reporting", "label": "Description of accounting policy for segment reporting [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Description of accounting policy for share-based payment transactions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r546" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "label": "Description of accounting policy for trade and other payables [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r546" ] }, "nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of judgement, estimates and assumptions", "label": "Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions [Policy Text Block]", "documentation": "Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r75", "r203" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Expected volatility, share options granted" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r127" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity (in years)", "label": "Option life, share options granted" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r127" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Risk free interest rate, share options granted" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r127" ] }, "nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of deferred income and contract liabilities", "label": "Detailed Information About Deferred Income And Contract Liabilities [Table Text Block]", "documentation": "Detailed Information About Deferred Income And Contract Liabilities" } } }, "auth_ref": [] }, "nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DetailedInformationAboutFinanceIncomeCostTableTextBlock", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Net Financial Income (loss)", "label": "Detailed Information About Finance Income (Cost) [Table Text Block]", "documentation": "Detailed Information About Finance Income (Cost)" } } }, "auth_ref": [] }, "nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other current liabilities", "label": "Detailed Information About Other Current Liabilities Explanatory [Table Text Block]", "documentation": "Detailed Information About Other Current Liabilities Explanatory" } } }, "auth_ref": [] }, "nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DetailedInformationAboutRefundLiabilitiesTableTextBlock", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of refund liabilities", "label": "Detailed Information About Refund Liabilities [Table Text Block]", "documentation": "Detailed Information About Refund Liabilities" } } }, "auth_ref": [] }, "nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of effect of changes in exchange rates", "label": "Detailed Information About The Effect Of Changes In Foreign Exchange Rates [Table Text Block]", "documentation": "Detailed Information About The Effect Of Changes In Foreign Exchange Rates" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per share (in euro per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r42", "r43" ] }, "ifrs-full_DirectorsRemunerationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DirectorsRemunerationExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofSignificantTransactionsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supervisory Board\u2019s fees", "label": "Directors' remuneration expense" } } }, "auth_ref": [ "r545" ] }, "nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of revenues and other income", "label": "Disclosur Of Disaggregation Of Revenues And Other Income [Table Text Block]", "documentation": "Disclosur Of Disaggregation Of Revenues And Other Income" } } }, "auth_ref": [] }, "nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Advances Loans and Lease Liabilities", "label": "Disclosure Of Advances Loans And Lease Liabilities [Table Text Block]", "documentation": "Disclosure Of Advances Loans And Lease Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfConsolidationExplanatory", "presentation": [ "http://nanobiotix.com/role/Consolidationprinciplesandmethods" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation principles and methods", "label": "Disclosure of basis of consolidation [text block]" } }, "en": { "role": { "documentation": "The disclosure of the basis used for consolidation." } } }, "auth_ref": [ "r541" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://nanobiotix.com/role/Cashandcashequivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Disclosure of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r541" ] }, "nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock", "presentation": [ "http://nanobiotix.com/role/CashandcashequivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cash and Cash Equivalents", "label": "Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block]", "documentation": "Disclosure Of Cash And Cash Equivalents Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingEstimatesLineItems", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of changes in accounting estimates [line items]", "label": "Disclosure of changes in accounting estimates [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfChangesInAccountingEstimatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingEstimatesTable", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of changes in accounting estimates [table]", "label": "Disclosure of changes in accounting estimates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the changes in accounting estimates." } } }, "auth_ref": [ "r77", "r204" ] }, "nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Changes in Research Tax Credit Receivables", "label": "Disclosure Of Changes In Research Tax Credit Receivables [Table Text Block]", "documentation": "Disclosure Of Changes In Research Tax Credit Receivables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://nanobiotix.com/role/SharecapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Detail of Share Capital Transactions", "label": "Disclosure of classes of share capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r196", "r284", "r316" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "http://nanobiotix.com/role/SharecapitalTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "http://nanobiotix.com/role/SharecapitalTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r196", "r284", "r316" ] }, "nbx_DisclosureOfCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Commitments [Abstract]", "documentation": "Disclosure Of Commitments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://nanobiotix.com/role/Commitments" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments", "label": "Disclosure of commitments [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r541" ] }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesLineItems", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [line items]", "label": "Disclosure of contingent liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesTable", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [table]", "label": "Disclosure of contingent liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } } }, "auth_ref": [ "r52", "r237" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Assumptions used to Measure Retirement Benefits", "label": "Disclosure of defined benefit plans [text block]" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r18", "r218" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [table]", "label": "Disclosure of defined benefit plans [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [table]", "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r18", "r218" ] }, "nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Depreciation, Amortization and Provision Expenses", "label": "Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Payroll Costs", "label": "Disclosure Of Detailed Information About Employee Benefits Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Employee Benefits Explanatory" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Financial Liabilities [Line Items]", "label": "Disclosure Of Detailed Information About Financial Liabilities [Line Items]", "documentation": "Disclosure Of Detailed Information About Financial Liabilities" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Financial Liabilities [Table]", "label": "Disclosure Of Detailed Information About Financial Liabilities [Table]", "documentation": "Disclosure Of Detailed Information About Financial Liabilities [Table]" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Changes in Non-Current Financial Assets", "label": "Disclosure Of Detailed Information About Non-Current Financial Assets [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Non-Current Financial Assets" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disclosure of Break Down of Other Current Assets", "label": "Disclosure Of Detailed Information About Other Current Assets Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Other Current Assets Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r15", "r217" ] }, "nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Research and Development Expense", "label": "Disclosure Of Detailed Information About Research And Development Expense Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Research And Development Expense Explanatory" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Selling, General and Administrative Expenses", "label": "Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Share-based Payments [Line Items]", "label": "Disclosure Of Detailed Information About Share-based Payments [Line Items]", "documentation": "Disclosure Of Detailed Information About Share-based Payments" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentsTable", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Share-based Payments [Table]", "label": "Disclosure Of Detailed Information About Share-based Payments [Table]", "documentation": "Disclosure Of Detailed Information About Share-based Payments" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade and other payables", "label": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory" } } }, "auth_ref": [] }, "nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disclosure of Break Down of Trade Receivables", "label": "Disclosure Of Detailed Information About Trade Receivables Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Trade Receivables Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]", "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r100", "r182" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://nanobiotix.com/role/Losspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r45" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://nanobiotix.com/role/Retirementobligations" ], "lang": { "en-us": { "role": { "verboseLabel": "Retirement obligations", "label": "Disclosure of employee benefits [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r26" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://nanobiotix.com/role/Netfinancialincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Net financial income (loss)", "label": "Disclosure of finance income (cost) [text block]" } } }, "auth_ref": [ "r541" ] }, "ifrs-full_DisclosureOfFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsExplanatory", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of details of non-current financial assets", "label": "Disclosure of financial assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r157", "r260" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [line items]", "label": "Disclosure of financial assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [table]", "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r157", "r260" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial instruments by type of interest rate [line items]", "label": "Disclosure of financial instruments by type of interest rate [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial instruments by type of interest rate [table]", "label": "Disclosure of financial instruments by type of interest rate [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial instruments, by type of interest rate." } } }, "auth_ref": [ "r539" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments included in the statement of financial position and impact on income", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r166" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [line items]", "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [table]", "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r141", "r148", "r157", "r260" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables", "http://nanobiotix.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Changes in Financial Liabilities", "verboseLabel": "Disclosure of details of financial liabilities", "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r157", "r260" ] }, "nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfFinancialLiabilitiesFootnoteTextBlock", "presentation": [ "http://nanobiotix.com/role/Financialliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Disclosure Of Financial Liabilities Footnote [Text Block]", "documentation": "Disclosure Of Financial Liabilities Footnote" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Changes In Financial Liabilities [Line Items]", "label": "Disclosure of financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Changes In Financial Liabilities [Table]", "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r157", "r260" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "General Information, Statement of Compliance and Basis of Presentation", "label": "Disclosure of general information about financial statements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r192", "r298" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://nanobiotix.com/role/Incometax" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period", "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r129" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period", "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r128" ] }, "nbx_DisclosureOfInformationRelatedToTheCompanyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfInformationRelatedToTheCompanyAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Information Related To The Company [Abstract]", "label": "Disclosure Of Information Related To The Company [Abstract]", "documentation": "Disclosure Of Information Related To The Company [Abstract]" } } }, "auth_ref": [] }, "nbx_DisclosureOfInformationRelatedToTheCompanyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfInformationRelatedToTheCompanyLineItems", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Information Related To The Company", "label": "Disclosure Of Information Related To The Company [Line Items]", "documentation": "Disclosure Of Information Related To The Company" } } }, "auth_ref": [] }, "nbx_DisclosureOfInformationRelatedToTheCompanyTable": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfInformationRelatedToTheCompanyTable", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Information Related To The Company [Table]", "label": "Disclosure Of Information Related To The Company [Table]", "documentation": "Disclosure Of Information Related To The Company [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://nanobiotix.com/role/Intangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r60" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [line items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r58", "r242" ] }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofImpactonDebtofSigningaDealthatwillGeneratePIKEarlyPaymentDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofImpactonDebtofSigningaDealthatwillGeneratePIKEarlyPaymentDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Table]", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities." } } }, "auth_ref": [ "r152", "r277" ] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Commitments for Retirement Benefits", "label": "Disclosure of net defined benefit liability (asset) [text block]" } }, "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r19", "r219" ] }, "nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfNonCurrentFinancialAssetsTextBlock", "presentation": [ "http://nanobiotix.com/role/Noncurrentfinancialassets" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets", "label": "Disclosure Of Non-current Financial Assets [Text Block]", "documentation": "Disclosure Of Non-current Financial Assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "presentation": [ "http://nanobiotix.com/role/Subsequentevents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent events", "label": "Disclosure of non-adjusting events after reporting period [text block]" } }, "en": { "role": { "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]" } } }, "auth_ref": [ "r0", "r205" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://nanobiotix.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]", "label": "Disclosure of non-adjusting events after reporting period [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://nanobiotix.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [table]", "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r0", "r205" ] }, "nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfNotesAndOtherExplanatoryInformationTextBlock", "presentation": [ "http://nanobiotix.com/role/Companyinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Company information", "label": "Disclosure of notes and other explanatory information [Text Block]", "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://nanobiotix.com/role/SharecapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Detail of Change in Founders' Warrants, Warrants and Free Shares", "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r538" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://nanobiotix.com/role/SharecapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Detail of Change in Stock Options", "label": "Disclosure of number and weighted average exercise prices of share options [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r124", "r257" ] }, "nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding", "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Line Items]", "documentation": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding" } } }, "auth_ref": [] }, "nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding", "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Table]", "documentation": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding" } } }, "auth_ref": [] }, "nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of number and weighted average remaining contractual life of founders' warrants, warrants, and free shares outstanding", "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of outstanding other equity Instruments [Table Text Block]", "documentation": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of number and weighted average remaining contractual life of share options outstanding", "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r125" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]", "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]", "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options." } } }, "auth_ref": [ "r125" ] }, "nbx_DisclosureOfOperatingExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfOperatingExpensesLineItems", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails", "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails", "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Expenses [Line Items]", "label": "Disclosure Of Operating Expenses [Line Items]", "documentation": "Disclosure Of Operating Expenses" } } }, "auth_ref": [] }, "nbx_DisclosureOfOperatingExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfOperatingExpensesTable", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails", "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails", "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Expenses [Table]", "label": "Disclosure Of Operating Expenses [Table]", "documentation": "Disclosure Of Operating Expenses [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsExplanatory", "presentation": [ "http://nanobiotix.com/role/Segmentreporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment reporting", "label": "Disclosure of operating segments [text block]" } }, "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } } }, "auth_ref": [ "r169" ] }, "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingExpenseExplanatory", "presentation": [ "http://nanobiotix.com/role/Operatingexpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Disclosure of other operating expense [text block]" } } }, "auth_ref": [ "r541" ] }, "nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfOtherOperatingIncomeExpensesTableTextBlock", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Other Operating Income (Expense)", "label": "Disclosure Of Other Operating Income (Expenses) [Table Text Block]", "documentation": "Disclosure Of Other Operating Income (Expenses)" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsExplanatory", "presentation": [ "http://nanobiotix.com/role/ProvisionsTables", "http://nanobiotix.com/role/RetirementobligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Changes in Provisions", "label": "Disclosure of other provisions [text block]" } }, "en": { "role": { "documentation": "The disclosure of other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r50", "r235" ] }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsLineItems", "presentation": [ "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails", "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Disclosure of other provisions [line items]", "terseLabel": "Disclosure of other provisions [table]", "label": "Disclosure of other provisions [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsTable", "presentation": [ "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails", "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other provisions [table]", "label": "Disclosure of other provisions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } } }, "auth_ref": [ "r50", "r235" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://nanobiotix.com/role/Propertyplantandequipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r17" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]", "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]", "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r15", "r217" ] }, "ifrs-full_DisclosureOfProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProvisionsExplanatory", "presentation": [ "http://nanobiotix.com/role/Provisions" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Disclosure of provisions [text block]" } }, "en": { "role": { "documentation": "The disclosure of provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r541" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r527" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Reconciliation of Changes in Lease Liabilities", "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r200", "r347" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://nanobiotix.com/role/Relatedparties" ], "lang": { "en-us": { "role": { "terseLabel": "Related parties", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r36" ] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://nanobiotix.com/role/Revenuesandotherincome" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues and other income", "label": "Disclosure of revenue [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r541" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Sensitivity Analysis for Actuarial Assumptions", "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]" } }, "en": { "role": { "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [domain]; Defined benefit obligation, at present value]" } } }, "auth_ref": [ "r24" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions [line items]", "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions [table]", "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions." } } }, "auth_ref": [ "r24" ] }, "nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share Capital [Abstract]", "label": "Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]", "documentation": "Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://nanobiotix.com/role/Sharecapital" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r198", "r285", "r317" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://nanobiotix.com/role/Sharebasedpayments" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r117" ] }, "nbx_DisclosureOfSignificantTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfSignificantTransactionsTextBlock", "presentation": [ "http://nanobiotix.com/role/Significanttransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Significant transactions", "label": "Disclosure Of Significant Transactions [Text Block]", "documentation": "Disclosure Of Significant Transactions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r7", "r211" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [Table]", "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r126", "r258" ] }, "nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Trade Payables and Other Current Liabilities [Line Items]", "label": "Disclosure of Trade Payables and Other Current Liabilities [Line Items]", "documentation": "Disclosure of Trade Payables and Other Current Liabilities" } } }, "auth_ref": [] }, "nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Trade Payables and Other Current Liabilities [Table]", "label": "Disclosure of Trade Payables and Other Current Liabilities [Table]", "documentation": "Disclosure of Trade Payables and Other Current Liabilities" } } }, "auth_ref": [] }, "nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "presentation": [ "http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and other current liabilities", "label": "Disclosure Of Trade Payables And Other Current Liabilities [Text Block]", "documentation": "Disclosure Of Trade Payables And Other Current Liabilities" } } }, "auth_ref": [] }, "nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Trade Receivables and Other Current Assets [Line Items]", "label": "Disclosure of Trade Receivables and Other Current Assets [Line Items]", "documentation": "Disclosure of Trade Receivables and Other Current Assets" } } }, "auth_ref": [] }, "nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Trade Receivables and Other Current Assets [Table]", "label": "Disclosure of Trade Receivables and Other Current Assets [Table]", "documentation": "Disclosure of Trade Receivables and Other Current Assets" } } }, "auth_ref": [] }, "nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock", "presentation": [ "http://nanobiotix.com/role/Tradereceivablesandothercurrentassets" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and other current assets", "label": "Disclosure Of Trade Receivables And Other Current Assets [Text Block]", "documentation": "Disclosure Of Trade Receivables And Other Current Assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://nanobiotix.com/role/RelatedpartiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of disclosure of significant transactions", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r33", "r227" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://nanobiotix.com/role/RelatedpartiesNarrativesDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [line items]", "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://nanobiotix.com/role/RelatedpartiesNarrativesDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [table]", "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r34", "r228" ] }, "nbx_DiscountOnOutstandingLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "DiscountOnOutstandingLoan", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount on outstanding loan", "label": "Discount on Outstanding Loan", "documentation": "Discount on Outstanding Loan" } } }, "auth_ref": [] }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decreases", "label": "Disposals, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r55", "r240" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Decreases", "label": "Disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r12", "r215" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r403" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r402", "r403", "r426" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r402", "r403", "r426", "r469" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r398" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r403" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r447" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r458" ] }, "nbx_EIBLoanGuaranteeBySubsidiariesMinimumPercentageOfConsolidatedGrossRevenuesTotalAssetsOrEBITDA": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EIBLoanGuaranteeBySubsidiariesMinimumPercentageOfConsolidatedGrossRevenuesTotalAssetsOrEBITDA", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EIB loan guarantee (as a percent)", "label": "EIB Loan Guarantee By Subsidiaries Minimum Percentage Of Consolidated Gross Revenues Total Assets Or EBITDA", "documentation": "EIB Loan Guarantee By Subsidiaries Minimum Percentage Of Consolidated Gross Revenues Total Assets Or EBITDA" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings per share [abstract]", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://nanobiotix.com/role/LosspershareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of basic and diluted loss per share", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r42" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates changes on cash", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r68", "r69" ] }, "nbx_EffectiveDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EffectiveDiscountRatePercent", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate percentage", "label": "Effective Discount Rate, Percent", "documentation": "Effective Discount Rate, Percent" } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofPayrollCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total payroll costs", "label": "Employee benefits expense" } } }, "auth_ref": [ "r193", "r289", "r328", "r390" ] }, "nbx_EmployeeRelatedVarianceAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EmployeeRelatedVarianceAdjustments", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other variance amount", "label": "Employee Related Variance Adjustments", "documentation": "Employee Related Variance Adjustments" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "nbx_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EmployeesMember", "presentation": [ "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees", "label": "Employees [Member]", "documentation": "Employees" } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitiesTable", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r400" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails", "http://nanobiotix.com/role/RelatedpartiesNarrativesDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r400" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r400" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInformationLineItems", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r509" ] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r400" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r400" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r510" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r452" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r505" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r505" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r505" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Equity at beginning of period", "periodEndLabel": "Equity at end of period", "terseLabel": "Equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r78", "r80", "r93", "r94", "r95", "r229", "r249", "r279", "r280", "r287", "r305", "r313" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r305" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDER\u2019S EQUITY", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r462" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r419", "r430", "r440", "r473" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r416", "r427", "r437", "r470" ] }, "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EstimatedFinancialEffectOfContingentLiabilities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated financial effect of contingent liabilities", "label": "Estimated financial effect of contingent liabilities" } }, "en": { "role": { "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r51", "r236" ] }, "nbx_EstimatedRoyaltyPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EstimatedRoyaltyPayments", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated royalty payments", "label": "Estimated Royalty Payments", "documentation": "Estimated Royalty Payments" } } }, "auth_ref": [] }, "nbx_EuropeanInvestmentBankLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EuropeanInvestmentBankLoanAgreementMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EIB Loan", "label": "European Investment Bank Loan Agreement [Member]", "documentation": "European Investment Bank Loan Agreement" } } }, "auth_ref": [] }, "nbx_EuropeanInvestmentBankLoanAgreementTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EuropeanInvestmentBankLoanAgreementTrancheTwoMember", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EIB fixed rate loan, tranche two", "label": "European Investment Bank Loan Agreement, Tranche Two [Member]", "documentation": "European Investment Bank Loan Agreement, Tranche Two" } } }, "auth_ref": [] }, "nbx_EventAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EventAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Event [Axis]", "label": "Event [Axis]", "documentation": "Event" } } }, "auth_ref": [] }, "nbx_EventDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EventDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Event [Domain]", "label": "Event [Domain]", "documentation": "Event [Domain]" } } }, "auth_ref": [] }, "nbx_EventOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EventOneMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Event One", "label": "Event One [Member]", "documentation": "Event One" } } }, "auth_ref": [] }, "nbx_EventTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "EventTwoMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Event Two", "label": "Event Two [Member]", "documentation": "Event Two" } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ExchangeDomain", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "nbx_ExecutiveBoardAndEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ExecutiveBoardAndEmployeesMember", "presentation": [ "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Board and Employees", "label": "Executive Board And Employees [Member]", "documentation": "Executive Board And Employees" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r468" ] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ExecutiveOfficerMember", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive", "label": "Executive Officer [Member]" } } }, "auth_ref": [] }, "nbx_ExercisePriceOfOptions": { "xbrltype": "pureItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ExercisePriceOfOptions", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price", "label": "Exercise Price Of Options", "documentation": "Exercise Price Of Options" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceOfOutstandingShareOptions2019", "presentation": [ "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock price", "label": "Exercise price of outstanding share options" } }, "en": { "role": { "documentation": "The exercise price of outstanding share options." } } }, "auth_ref": [ "r125" ] }, "nbx_ExercisePriceOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ExercisePriceOtherEquityInstrumentsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in euro per share)", "label": "Exercise Price, Other Equity Instruments Granted", "documentation": "Exercise Price, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in euros per share)", "label": "Exercise price, share options granted" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r127" ] }, "nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ExpectedDividendAsPercentageOtherEquityInstrumentsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yield", "label": "Expected Dividend As Percentage, Other Equity Instruments Granted", "documentation": "Expected Dividend As Percentage, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yield", "label": "Expected dividend as percentage, share options granted" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r127" ] }, "nbx_ExpectedVolatilityOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Expected Volatility, Other Equity Instruments Granted", "documentation": "Expected Volatility, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense for the year", "label": "Expense from equity-settled share-based payment transactions" } } }, "auth_ref": [ "r130" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofPayrollCostsDetails", "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "negatedTerseLabel": "Share-based payments", "label": "Expense from share-based payment transactions with employees" } } }, "auth_ref": [ "r545" ] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "FR", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "France", "label": "FRANCE" } } }, "auth_ref": [] }, "nbx_FairValueProfitLossImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "FairValueProfitLossImpact", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofImpactonDebtofSigningaDealthatwillGeneratePIKEarlyPaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "P&L impact", "label": "Fair Value Profit (Loss) Impact", "documentation": "Fair Value Profit (Loss) Impact" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Financial expenses", "label": "Finance costs" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income", "totalLabel": "Total financial income", "label": "Finance income" } } }, "auth_ref": [ "r552" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net financial income (loss)", "label": "Finance income (cost)" } } }, "auth_ref": [ "r552" ] }, "nbx_FinancialAgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "FinancialAgreementAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Agreement [Axis]", "label": "Financial Agreement [Axis]", "documentation": "Financial Agreement [Axis]" } } }, "auth_ref": [] }, "nbx_FinancialAgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "FinancialAgreementDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Agreement [Domain]", "label": "Financial Agreement [Domain]", "documentation": "Financial Agreement [Domain]" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total financial assets", "label": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r140", "r145", "r146", "r150", "r273", "r274", "r276", "r363" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets and liabilities carried at amortized cost", "label": "Financial assets at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r160", "r263" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostMember", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at amortised cost, class", "label": "Financial assets at amortised cost, class [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r163", "r180", "r267" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total financial assets, at fair value", "label": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets carried at fair value through profit or loss", "label": "Financial assets at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r158", "r261" ] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial liabilities", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities at amortised cost", "label": "Financial liabilities at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r161", "r264" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities, at fair value", "label": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities at fair value through profit or loss, category", "label": "Financial liabilities at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r159", "r262" ] }, "ifrs-full_FinancialLiabilitiesCarryingAmountImmediatelyAfterInitialApplicationOfIFRS9": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesCarryingAmountImmediatelyAfterInitialApplicationOfIFRS9", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities, carrying amount immediately after initial application of IFRS 9", "label": "Financial liabilities, carrying amount immediately after initial application of IFRS 9" } }, "en": { "role": { "documentation": "The carrying amount of financial liabilities immediately after the initial application of IFRS 9. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r154" ] }, "nbx_FirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "FirstTrancheMember", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Tranche", "label": "First Tranche [Member]", "documentation": "First Tranche" } } }, "auth_ref": [] }, "nbx_FixedAndVariableInterestExpensesAccrualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "FixedAndVariableInterestExpensesAccrualAmount", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed and variable interest expenses accrual amount", "label": "Fixed And Variable Interest Expenses Accrual Amount", "documentation": "Fixed And Variable Interest Expenses Accrual Amount" } } }, "auth_ref": [] }, "nbx_FixedFlowRateMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "FixedFlowRateMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Flow Rate", "label": "Fixed Flow Rate [Member]", "documentation": "Fixed Flow Rate" } } }, "auth_ref": [] }, "ifrs-full_FixedInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FixedInterestRateMember", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate", "label": "Fixed interest rate [member]" } }, "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r539" ] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixtures, fittings and installations", "label": "Fixtures and fittings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_FloatingInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FloatingInterestRateMember", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable interest rate", "label": "Floating interest rate [member]" } }, "en": { "role": { "documentation": "This member stands for a non-fixed interest rate. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r539" ] }, "nbx_ForecastTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ForecastTransactionsMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast Transactions", "label": "Forecast Transactions [Member]", "documentation": "Forecast Transactions" } } }, "auth_ref": [] }, "nbx_ForecastedSubscriptionSettlementFee": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ForecastedSubscriptionSettlementFee", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate subscription price", "label": "Forecasted Subscription Settlement Fee", "documentation": "Aggregate Subscription Price" } } }, "auth_ref": [] }, "nbx_ForeignExchangeOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ForeignExchangeOptionsMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange options", "label": "Foreign exchange options [Member]", "documentation": "Foreign exchange options" } } }, "auth_ref": [] }, "nbx_ForestedFeeBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ForestedFeeBasis", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription price funded", "label": "Forested Fee Basis", "documentation": "Forested Fee Basis" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r423", "r434", "r444", "r477" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r423", "r434", "r444", "r477" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r423", "r434", "r444", "r477" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r423", "r434", "r444", "r477" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r423", "r434", "r444", "r477" ] }, "nbx_FormerEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "FormerEmployeesMember", "presentation": [ "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Former employees", "label": "Former Employees [Member]", "documentation": "Former Employees" } } }, "auth_ref": [] }, "nbx_FormerExecutiveBoardMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "FormerExecutiveBoardMembersMember", "presentation": [ "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Former Executive Board members", "label": "Former Executive Board Members [Member]", "documentation": "Former Executive Board Members" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r457" ] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Actuarial gains or losses recognized in other comprehensive income", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r23", "r222" ] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustment", "verboseLabel": "Foreign exchange gain (loss)", "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax" } }, "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange losses", "label": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r27", "r223", "r297" ] }, "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains (losses) on financial assets at fair value through profit or loss", "label": "Gains (losses) on financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r133", "r266" ] }, "ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gains (losses) on financial liabilities at fair value through profit or loss", "label": "Gains (losses) on financial liabilities at fair value through profit or loss" } }, "en": { "role": { "documentation": "The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r133", "r266" ] }, "nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract", "lang": { "en-us": { "role": { "terseLabel": "General Information, Statement of Compliance and Basis of Presentation [Abstract]", "label": "General Information, Statement of Compliance and Basis of Presentation [Abstract]", "documentation": "General Information, Statement of Compliance and Basis of Presentation" } } }, "auth_ref": [] }, "nbx_GlobalTrialClinicalAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "GlobalTrialClinicalAgreementMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Trial Clinical Agreement", "label": "Global Trial Clinical Agreement [Member]", "documentation": "Global Trial Clinical Agreement" } } }, "auth_ref": [] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails", "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross book value of intangible assets", "terseLabel": "Gross book value of tangible assets", "label": "Gross carrying amount [member]" } } }, "auth_ref": [ "r10", "r53", "r63", "r66", "r131", "r146", "r150", "r213", "r238", "r245", "r248", "r274", "r276", "r363" ] }, "ifrs-full_GrossLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossLeaseLiabilities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Gross lease liabilities" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r104", "r185", "r365" ] }, "nbx_HCRRoyaltyFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "HCRRoyaltyFinancingMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HCR Royalty Financing", "label": "HCR Royalty Financing [Member]", "documentation": "HCR Royalty Financing" } } }, "auth_ref": [] }, "ifrs-full_HedgedItemsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "HedgedItemsAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedged items [axis]", "label": "Hedged items [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r138", "r269" ] }, "ifrs-full_HedgedItemsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "HedgedItemsDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedged items [domain]", "label": "Hedged items [domain]" } }, "en": { "role": { "documentation": "This member stands for hedged items. A hedged item can be a recognised asset or liability, an unrecognised firm commitment, a forecast transaction or a net investment in a foreign operation. The hedged item can be: (a) a single item; or (b) a group of items (subject to paragraphs 6.6.1\u20136.6.6 and B6.6.1\u2013B6.6.16 of IFRS 9). A hedged item can also be a component of such an item or group of items (see paragraphs 6.3.7 and B6.3.7\u2013B6.3.25 of IFRS 9). This member also represents the standard value for the 'Hedged items' axis if no other member is used." } } }, "auth_ref": [ "r138", "r269" ] }, "ifrs-full_HedgingInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "HedgingInstrumentsAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging instruments [axis]", "label": "Hedging instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r135", "r137", "r268" ] }, "ifrs-full_HedgingInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "HedgingInstrumentsDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging instruments [domain]", "label": "Hedging instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used." } } }, "auth_ref": [ "r135", "r137", "r268" ] }, "nbx_HigherBonusPayrollExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "HigherBonusPayrollExpense", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Higher bonus payroll expense", "label": "Higher Bonus Payroll Expense", "documentation": "Higher Bonus Payroll Expense" } } }, "auth_ref": [] }, "nbx_ICONPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ICONPlcMember", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ICON Plc", "label": "ICON Plc [Member]", "documentation": "ICON Plc" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r402", "r403", "r426" ] }, "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable assets acquired (liabilities assumed)", "label": "Identifiable assets acquired (liabilities assumed)" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r357", "r358", "r383" ] }, "nbx_ImpactOfDebtAmendmentOnProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ImpactOfDebtAmendmentOnProfitLoss", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of the Janssen amendment on profit or loss", "label": "Impact of Debt Amendment on Profit (Loss)", "documentation": "Impact of Debt Amendment on Profit (Loss)" } } }, "auth_ref": [] }, "ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Income, expense, gains or losses of financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax", "terseLabel": "Effective tax expense", "totalLabel": "Effective tax expense", "label": "Tax expense (income)" } } }, "auth_ref": [ "r1", "r3", "r4", "r38", "r92", "r168", "r206", "r207", "r208", "r324" ] }, "ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax impact", "label": "Income tax relating to exchange differences on translation of foreign operations included in other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to exchange differences on the translation of financial statements of foreign operations. [Refer: Other comprehensive income; Reserve of exchange differences on translation]" } } }, "auth_ref": [ "r2", "r325" ] }, "ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax impact", "label": "Income tax relating to remeasurements of defined benefit plans included in other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to remeasurements of defined benefit plans. [Refer: Other comprehensive income; Reserve of remeasurements of defined benefit plans; Defined benefit plans [domain]]" } } }, "auth_ref": [ "r2", "r325" ] }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS_1": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax paid", "label": "Income taxes paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } } }, "auth_ref": [ "r536" ] }, "ifrs-full_IncomeTaxesPaidRefundAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundAbstract", "lang": { "en-us": { "role": { "label": "Income taxes paid (refund) [abstract]" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseFromPriorPeriodAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseFromPriorPeriodAdjustments", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior period adjustments", "label": "Increase (Decrease) From Prior Period Adjustments", "documentation": "Increase (Decrease) From Prior Period Adjustments" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseInBonusPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseInBonusPayments", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in bonus payments", "label": "Increase (Decrease) in Bonus Payments", "documentation": "Increase (Decrease) in Bonus Payments" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails", "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "verboseLabel": "Increase in cash and cash equivalents", "negatedLabel": "Increase in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r74", "r202" ] }, "ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInExistingProvisionsOtherProvisions", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Provision for disputes and charges", "label": "Increase in existing provisions, other provisions" } }, "en": { "role": { "documentation": "The increase in existing other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r47", "r232" ] }, "ifrs-full_IncreaseDecreaseInFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInFinancialAssetsAbstract", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in financial assets [abstract]", "label": "Increase (decrease) in financial assets [abstract]" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseInNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseInNumberOfEmployees", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase (decrease) in number of employees", "terseLabel": "Increase in number of employees", "label": "Increase (Decrease) In Number Of Employees", "documentation": "Increase (Decrease) In Number Of Employees" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in payroll tax and other payroll liabilities", "label": "Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current", "documentation": "Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseInPurchasesFeesAndOtherExpenses", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (decrease) in rent, fees, and other expenses", "label": "Increase (Decrease) In Purchases, Fees, And Other Expenses", "documentation": "Increase (Decrease) In Purchases, Fees, And Other Expenses" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in purchases, sub-contracting and other expenses", "label": "Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses", "documentation": "Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseInResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseInResearchTaxCredit", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease of research tax credit", "label": "Increase (Decrease) in Research Tax Credit", "documentation": "Increase (Decrease) in Research Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Changes in operating working capital", "terseLabel": "Capital increase", "label": "Increase (decrease) in working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r535" ] }, "nbx_IncreaseDecreaseOnFairValueVariation": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseOnFairValueVariation", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Losses on fair value variation", "label": "Increase (Decrease) On Fair Value Variation", "documentation": "Increase (Decrease) On Fair Value Variation" } } }, "auth_ref": [] }, "nbx_IncreaseDecreasePayrollExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreasePayrollExpense", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase/ decrease in employee benefit expense", "label": "Increase (Decrease) Payroll Expense", "documentation": "Increase (Decrease) Payroll Expense" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) related to adjustments for income forecast projections", "label": "Increase Decrease Related To Adjustments For Income Forecast Projections", "documentation": "Increase Decrease Related To Adjustments For Income Forecast Projections" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative variable interest expense accrual", "label": "Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of prior period loss", "label": "Increase (decrease) through appropriation of retained earnings, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r543" ] }, "nbx_IncreaseDecreaseThroughCumulativeFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseThroughCumulativeFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative fixed interest expense accrual", "label": "Increase (Decrease) Through Cumulative Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Cumulative Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in loans and conditional advances", "label": "Increase (Decrease) Through Decrease In Loans And Conditional Advances, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Decrease In Loans And Conditional Advances, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal received / New contracts", "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } } }, "auth_ref": [ "r72", "r199" ] }, "ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssets", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustments", "label": "Increase (decrease) through foreign exchange, financial assets" } }, "en": { "role": { "documentation": "The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]" } } }, "auth_ref": [ "r359", "r374", "r384" ] }, "nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Impact of discounting and accretion", "label": "Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of discounting and catch-up", "label": "Increase (Decrease) Through Impact Of Discounting And Catch up, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Impact Of Discounting And Catch up, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indexation effect on current lease commitment", "label": "Increase (Decrease) Through Indexation Effect On Current Lease Commitment, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Indexation Effect On Current Lease Commitment, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r56" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Increase (decrease) through net exchange differences, other provisions" } }, "en": { "role": { "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]" } } }, "auth_ref": [ "r524" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Increase (decrease) through net exchange differences, property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r13" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share based payment", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer", "label": "Increase (decrease) through transfers and other changes, property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r513" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersFinancialAssets", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Increase (decrease) through transfers, financial assets" } }, "en": { "role": { "documentation": "The increase (decrease) in financial assets resulting from transfers. [Refer: Financial assets]" } } }, "auth_ref": [ "r359", "r362", "r374", "r384", "r387" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer", "label": "Increase (decrease) through transfers, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r526" ] }, "nbx_IncreaseInCommitmentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IncreaseInCommitmentPercentage", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in commitment, percent", "label": "Increase in Commitment Percentage", "documentation": "Increase in Commitment Percentage" } } }, "auth_ref": [] }, "ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseThroughOriginationOrPurchaseFinancialAssets", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase through origination or purchase, financial assets" } }, "en": { "role": { "documentation": "The increase in financial assets resulting from origination or purchase. [Refer: Financial assets]" } } }, "auth_ref": [ "r359", "r360", "r374", "r384", "r385" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r423", "r434", "r444", "r468", "r477", "r481", "r489" ] }, "nbx_InitialFixedReturnAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InitialFixedReturnAmount", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial fixed return amount", "label": "Initial Fixed Return Amount", "documentation": "Initial Fixed Return Amount" } } }, "auth_ref": [] }, "nbx_InitialFixedReturnAmountCap": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InitialFixedReturnAmountCap", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial fixed return amount capped", "label": "Initial Fixed Return Amount Cap", "documentation": "Initial Fixed Return Amount Capped" } } }, "auth_ref": [] }, "nbx_InitialFixedReturnRateAsPercentageOfSubscription": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InitialFixedReturnRateAsPercentageOfSubscription", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription price if repaid on or prior percent", "label": "Initial Fixed Return Rate As Percentage of Subscription", "documentation": "Initial Fixed Return Rate As Percentage of Subscription" } } }, "auth_ref": [] }, "nbx_InitialFixedReturnRateAsPercentageOfSubscriptionPrice": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InitialFixedReturnRateAsPercentageOfSubscriptionPrice", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial fixed return rate as percentage of subscription price", "label": "Initial Fixed Return Rate As Percentage of Subscription Price", "documentation": "Initial Fixed Return Rate As Percentage of Subscription Price" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r487" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r404", "r493" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r404", "r493" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r404", "r493" ] }, "nbx_InstallmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InstallmentAxis", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Installment [Axis]", "label": "Installment [Axis]", "documentation": "Installment" } } }, "auth_ref": [] }, "nbx_InstallmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InstallmentDomain", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Installment [Domain]", "label": "Installment [Domain]", "documentation": "Installment [Domain]" } } }, "auth_ref": [] }, "nbx_InstallmentOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InstallmentOneMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Installment One", "label": "Installment One [Member]", "documentation": "Installment One" } } }, "auth_ref": [] }, "nbx_InstallmentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InstallmentPayment", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value debt considering amount", "label": "Installment Payment", "documentation": "Installment Payment" } } }, "auth_ref": [] }, "nbx_InstallmentTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InstallmentTwoMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Installment Two", "label": "Installment Two [Member]", "documentation": "Installment Two" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "periodStartLabel": "Intangible assets at beginning of period", "periodEndLabel": "Intangible assets at end of period", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r57", "r241", "r300" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets other than goodwill [member]", "label": "Intangible assets other than goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r335", "r355", "r380", "r382" ] }, "nbx_IntellectualPropertyServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "IntellectualPropertyServicesMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intellectual Property Services", "label": "Intellectual Property Services [Member]", "documentation": "Intellectual Property Services" } } }, "auth_ref": [] }, "nbx_InterestCostOfRoyaltyFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InterestCostOfRoyaltyFinancing", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost of royalty financing", "label": "Interest Cost Of Royalty Financing", "documentation": "Interest Cost Of Royalty Financing" } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interests / discounting costs", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)" } } }, "auth_ref": [ "r21", "r221" ] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on borrowings", "label": "Interest expense on borrowings" } } }, "auth_ref": [ "r545" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Lease debt interests", "label": "Interest expense on lease liabilities" } } }, "auth_ref": [ "r103", "r184" ] }, "nbx_InterestFreeAdvanceToCuradigmBPIFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InterestFreeAdvanceToCuradigmBPIFranceMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Curadigm interest-free Bpifrance advance", "label": "Interest-free Advance To Curadigm, BPI France [Member]", "documentation": "Interest-free Advance To Curadigm, BPI France" } } }, "auth_ref": [] }, "nbx_InterestFreeLoanBPIFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InterestFreeLoanBPIFranceMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest-free Bpifrance loan", "label": "Interest-free Loan, BPI France [Member]", "documentation": "Interest-free Loan, BPI France" } } }, "auth_ref": [] }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeOnCashAndCashEquivalents", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income on cash and cash equivalents", "label": "Interest income on cash and cash equivalents" } } }, "auth_ref": [ "r545" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r70" ] }, "nbx_InterestPayablePaymentInKind": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InterestPayablePaymentInKind", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable, Payment-In-Kind", "documentation": "Interest Payable, Payment-In-Kind" } } }, "auth_ref": [] }, "nbx_InterestRepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "InterestRepayments", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest repayments", "label": "Interest Repayments", "documentation": "Interest Repayments" } } }, "auth_ref": [] }, "ifrs-full_InterestRevenueExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestRevenueExpense", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "negatedLabel": "Interest expense", "label": "Interest income (expense)" } } }, "auth_ref": [ "r169", "r174", "r552" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Capital increase", "terseLabel": "Capital increase", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r293" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r389", "r395" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital Ordinary shares", "verboseLabel": "Share Capital", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r295" ] }, "nbx_JNJ1900NBTXR3Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "JNJ1900NBTXR3Member", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "JNJ-1900 (NBTXR3)", "label": "JNJ-1900 (NBTXR3) [Member]", "documentation": "JNJ-1900 (NBTXR3)" } } }, "auth_ref": [] }, "nbx_JanssenMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "JanssenMember", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Janssen", "label": "Janssen [Member]", "documentation": "Janssen" } } }, "auth_ref": [] }, "nbx_JanssenPharmaceuticaBVMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "JanssenPharmaceuticaBVMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Janssen Pharmaceutica BV", "label": "Janssen Pharmaceutica BV [Member]", "documentation": "Janssen Pharmaceutica BV" } } }, "auth_ref": [] }, "nbx_JanssenPharmaceuticaNVMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "JanssenPharmaceuticaNVMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Janssen", "label": "Janssen Pharmaceutica NV [Member]", "documentation": "Janssen Pharmaceutica NV" } } }, "auth_ref": [] }, "nbx_JohnsonJohnsonInnovationsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "JohnsonJohnsonInnovationsMember", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails", "http://nanobiotix.com/role/RelatedpartiesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "JJDC", "label": "Johnson & Johnson Innovations [Member]", "documentation": "Johnson & Johnson Innovations" } } }, "auth_ref": [] }, "nbx_KeplerCheuvreuxSubscriptionAgreementPACEOMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "KeplerCheuvreuxSubscriptionAgreementPACEOMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Kepler Cheuvreux Subscription Agreement PACEO", "label": "Kepler Cheuvreux Subscription Agreement PACEO [Member]", "documentation": "Kepler Cheuvreux Subscription Agreement PACEO" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofSignificantTransactionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total compensation to related parties", "label": "Key management personnel compensation" } } }, "auth_ref": [ "r31", "r225" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofSignificantTransactionsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Key management personnel compensation, share-based payment" } } }, "auth_ref": [ "r30" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofSignificantTransactionsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries, wages and benefits", "label": "Key management personnel compensation, short-term employee benefits" } } }, "auth_ref": [ "r29" ] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "More than 5 years", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r105", "r106", "r115", "r187", "r190", "r364", "r372", "r375" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Between 1 and 3\u00a0years", "label": "Later than one year and not later than three years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than three years." } } }, "auth_ref": [ "r364", "r370", "r375" ] }, "ifrs-full_LaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after more than 12 months", "label": "Later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year." } } }, "auth_ref": [ "r307" ] }, "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due between 6 and 12 months", "label": "Later than six months and not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than six months and not later than one year." } } }, "auth_ref": [ "r364", "r369", "r375" ] }, "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due between 3 and 6 months", "label": "Later than three months and not later than six months [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three months and not later than six months." } } }, "auth_ref": [ "r364", "r368", "r375" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Between 3 and 5\u00a0years", "label": "Later than three years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than five years." } } }, "auth_ref": [ "r364", "r371", "r375" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Lease liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r346", "r350" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails", "http://nanobiotix.com/role/RelatedpartiesNarrativesDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "nbx_LegalFeesAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "LegalFeesAndExpenses", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal fees", "label": "Legal Fees and Expenses", "documentation": "Legal Fees and Expenses" } } }, "auth_ref": [] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r93", "r94", "r95", "r169", "r173", "r279", "r280", "r305" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Liabilities arising from financing activities at beginning of period", "periodEndLabel": "Liabilities arising from financing activities at end of period", "label": "Liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r200", "r347" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofImpactonDebtofSigningaDealthatwillGeneratePIKEarlyPaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [axis]", "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r200", "r347" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesDomain", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofImpactonDebtofSigningaDealthatwillGeneratePIKEarlyPaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities", "label": "Liabilities arising from financing activities [domain]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r200", "r347" ] }, "nbx_LiabilitiesRelatedToFinancingActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "LiabilitiesRelatedToFinancingActivitiesMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities Related To Financing Activities", "label": "Liabilities Related To Financing Activities [Member]", "documentation": "Liabilities Related To Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Provisions of retirement benefits at beginning of period", "periodEndLabel": "Provisions of retirement benefits at end of period", "label": "Net defined benefit liability (asset)" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r19", "r219" ] }, "nbx_LianBioNBTXR3AndCetuximabMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "LianBioNBTXR3AndCetuximabMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LianBio, NBTXR3 and Cetuximab", "label": "LianBio, NBTXR3 And Cetuximab [Member]", "documentation": "LianBio, NBTXR3 And Cetuximab" } } }, "auth_ref": [] }, "nbx_LianBioNBTXR3Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "LianBioNBTXR3Member", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LianBio, NBTXR3", "label": "LianBio, NBTXR3 [Member]", "documentation": "LianBio, NBTXR3" } } }, "auth_ref": [] }, "ifrs-full_LoansAndAdvances": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LoansAndAdvances", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans and advances", "label": "Loans and advances" } }, "en": { "role": { "documentation": "The amount of loans and advances the entity has made." } } }, "auth_ref": [ "r548" ] }, "ifrs-full_LoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LoansReceived", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans received", "label": "Loans received" } }, "en": { "role": { "documentation": "The amount of loans received." } } }, "auth_ref": [ "r545" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term borrowings", "label": "Long-term borrowings [member]" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r346", "r350" ] }, "nbx_LumpSumRetirementBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "LumpSumRetirementBenefitsMember", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lump-sum retirement benefits", "label": "Lump-Sum Retirement Benefits [Member]", "documentation": "Lump-Sum Retirement Benefits" } } }, "auth_ref": [] }, "nbx_MDAndersonCancerCenterNBTXR3Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MDAndersonCancerCenterNBTXR3Member", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MD Anderson Cancer Center, NBTXR3", "label": "MD Anderson Cancer Center, NBTXR3 [Member]", "documentation": "MD Anderson Cancer Center, NBTXR3" } } }, "auth_ref": [] }, "ifrs-full_MachineryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MachineryMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technical equipment", "label": "Machinery [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r330" ] }, "nbx_MajorCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MajorCollaborationAgreementMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Collaboration Agreement", "label": "Major Collaboration Agreement [Member]", "documentation": "Major Collaboration Agreement" } } }, "auth_ref": [] }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorOrdinaryShareTransactionsMember", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major ordinary share transactions", "label": "Major ordinary share transactions [member]" } }, "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r329", "r381" ] }, "srt_ManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ManagementMember", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management", "label": "Management [Member]" } } }, "auth_ref": [] }, "nbx_MarketRateMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MarketRateMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market Rate", "label": "Market Rate [Member]", "documentation": "Market Rate" } } }, "auth_ref": [] }, "nbx_MasterServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MasterServiceAgreementMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Master Service Agreement", "label": "Master Service Agreement [Member]", "documentation": "Master Service Agreement" } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r101", "r105", "r106", "r107", "r108", "r109", "r115", "r136", "r153", "r181", "r183", "r188", "r191", "r271", "r308", "r333", "r364" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity", "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r101", "r105", "r106", "r107", "r108", "r109", "r115", "r136", "r181", "r183", "r188", "r191", "r271", "r308", "r333", "r364", "r373" ] }, "nbx_MaximumAnnualRoyaltyRepayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MaximumAnnualRoyaltyRepayment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum annual royalty repayment", "label": "Maximum Annual Royalty Repayment", "documentation": "Maximum Annual Royalty Repayment" } } }, "auth_ref": [] }, "nbx_MaximumBorrowingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MaximumBorrowingAmount", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing amount", "label": "Maximum Borrowing Amount", "documentation": "Maximum Borrowing Amount" } } }, "auth_ref": [] }, "ifrs-full_MaximumExposureToCreditRisk": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaximumExposureToCreditRisk", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum exposure to credit risk", "label": "Maximum exposure to credit risk" } }, "en": { "role": { "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]" } } }, "auth_ref": [ "r147" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [] }, "nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee", "presentation": [ "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum term of options granted for share-based payment arrangement in the event of death or disability of optionee", "label": "Maximum Term Of Options Granted For Share-Based Payment Arrangement In The Event Of Death Or Disability Of Optionee", "documentation": "Maximum Term Of Options Granted For Share-Based Payment Arrangement In The Event Of Death Or Disability Of Optionee" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r460" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r460" ] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement [axis]", "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r61", "r65", "r93", "r247", "r279" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement [domain]", "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r61", "r65", "r93", "r247", "r279" ] }, "nbx_MilestonePaymentDefermentPeriodAfterEnrollment": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MilestonePaymentDefermentPeriodAfterEnrollment", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment, deferment period", "label": "Milestone Payment, Deferment Period After Enrollment", "documentation": "Milestone Payment, Deferment Period After Enrollment" } } }, "auth_ref": [] }, "nbx_MilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MilestonePaymentMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Payment", "label": "Milestone Payment [Member]", "documentation": "Milestone Payment" } } }, "auth_ref": [] }, "nbx_MilestonePaymentSecondInstallment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MilestonePaymentSecondInstallment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second installment payment", "label": "Milestone Payment, Second Installment", "documentation": "Milestone Payment, Second Installment" } } }, "auth_ref": [] }, "nbx_MilestoneThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MilestoneThreeMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Three", "label": "Milestone Three [Member]", "documentation": "Milestone Three" } } }, "auth_ref": [] }, "nbx_MilestoneTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MilestoneTwoMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Two", "label": "Milestone Two [Member]", "documentation": "Milestone Two" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [] }, "nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum threshold to provide additional know-how to third party under collaboration agreement", "label": "Minimum Threshold To Provide Additional Know-How To Third Party Under Collaboration Agreement", "documentation": "Minimum Threshold To Provide Additional Know-How To Third Party Under Collaboration Agreement" } } }, "auth_ref": [] }, "nbx_MinusTenPercentMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "MinusTenPercentMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales -10%", "label": "Minus Ten Percent [Member]", "documentation": "Minus Ten Percent" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other operating expenses", "label": "Miscellaneous other operating expense" } } }, "auth_ref": [ "r545" ] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Miscellaneous other operating income" } } }, "auth_ref": [ "r545" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r480" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r488" ] }, "nbx_NANORAY312Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NANORAY312Member", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NONORAY-312", "label": "NANORAY-312 [Member]", "documentation": "NANORAY-312" } } }, "auth_ref": [] }, "nbx_NBTXR3Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NBTXR3Member", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NBTXR3", "label": "NBTXR3 [Member]", "documentation": "NBTXR3" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r461" ] }, "nbx_NanoCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NanoCorpMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nano Corp", "label": "Nano Corp [Member]", "documentation": "Nano Corp" } } }, "auth_ref": [] }, "nbx_NanobiotixCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NanobiotixCorpMember", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/RelatedpartiesNarrativesDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nanobiotix Corp.", "label": "Nanobiotix Corp. [Member]", "documentation": "Nanobiotix Corp." } } }, "auth_ref": [] }, "nbx_NanobiotixSAMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NanobiotixSAMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nanobiotix S.A.", "label": "Nanobiotix S.A. [Member]", "documentation": "Nanobiotix S.A." } } }, "auth_ref": [] }, "nbx_NetAmountsReceivablePayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NetAmountsReceivablePayableRelatedPartyTransactions", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net receivables (liabilities)", "label": "Net Amounts Receivable Payable Related Party Transactions", "documentation": "Net Amounts Receivable Payable Related Party Transactions" } } }, "auth_ref": [] }, "nbx_NetCollectionsPaymentsFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NetCollectionsPaymentsFromRelatedParty", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net collections", "label": "Net Collections (Payments) From Related Party", "documentation": "Net Collections (Payments) From Related Party" } } }, "auth_ref": [] }, "ifrs-full_NetDebt": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDebt", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofImpactonDebtofSigningaDealthatwillGeneratePIKEarlyPaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total debt at amortized cost", "label": "Net debt" } }, "en": { "role": { "documentation": "The amount of net debt of the entity." } } }, "auth_ref": [ "r545" ] }, "ifrs-full_NetForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetForeignExchangeGain", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange gains", "label": "Net foreign exchange gain" } } }, "auth_ref": [ "r522", "r547" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "nbx_NetLossForThePeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NetLossForThePeriodMember", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss for the period", "label": "Net Loss For The Period [Member]", "documentation": "Net Loss For The Period" } } }, "auth_ref": [] }, "nbx_NetOfPayableReduction": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NetOfPayableReduction", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net of payable reduction", "label": "Net Of Payable Reduction", "documentation": "Net Of Payable Reduction" } } }, "auth_ref": [] }, "nbx_NetOfPayableReductionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NetOfPayableReductionNet", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net of payable reduction, net", "label": "Net Of Payable Reduction, Net", "documentation": "Net Of Payable Reduction, Net" } } }, "auth_ref": [] }, "nbx_NettingMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NettingMember", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Netting", "label": "Netting [Member]", "documentation": "Netting" } } }, "auth_ref": [] }, "nbx_NoDealBeforeAugust2023Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NoDealBeforeAugust2023Member", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofImpactonDebtofSigningaDealthatwillGeneratePIKEarlyPaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "No Deal Before August 2023 [Member]", "label": "No Deal Before August 2023 [Member]", "documentation": "No Deal Before August 2023" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "No Trading Symbol Flag", "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "nbx_NonClinicalsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonClinicalsMember", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-clinicals", "label": "Non-clinicals [Member]", "documentation": "Non-clinicals" } } }, "auth_ref": [] }, "nbx_NonCurrentFinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonCurrentFinancialAssetsMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets", "label": "Non-Current Financial Assets [Member]", "documentation": "Non-Current Financial Assets" } } }, "auth_ref": [] }, "nbx_NonCurrentFinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonCurrentFinancialLiabilitiesMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial liabilities", "label": "Non Current Financial Liabilities [Member]", "documentation": "Non Current Financial Liabilities" } } }, "auth_ref": [] }, "nbx_NonCurrentOtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonCurrentOtherProvisionsMember", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Non-current provisions", "label": "Non-Current Other Provisions [Member]", "documentation": "Non-Current Other Provisions" } } }, "auth_ref": [] }, "nbx_NonCurrentRightsPlacedInTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonCurrentRightsPlacedInTrustMember", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rights Placed in Trust", "label": "Non-current, Rights Placed in Trust [Member]", "documentation": "Non-current, Rights Placed in Trust" } } }, "auth_ref": [] }, "nbx_NonCurrentSecurityDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonCurrentSecurityDepositMember", "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposits paid", "label": "Non-current, Security Deposit [Member]", "documentation": "Non-current, Security Deposit" } } }, "auth_ref": [] }, "nbx_NonDilutiveFinancingAgreementBPIFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonDilutiveFinancingAgreementBPIFranceMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Dilutive Financing Agreement, BPI France", "verboseLabel": "Bpifrance \"PGE\"", "label": "Non-Dilutive Financing Agreement, BPI France [Member]", "documentation": "Non-Dilutive Financing Agreement, BPI France" } } }, "auth_ref": [] }, "nbx_NonDilutiveFinancingAgreementHSBCFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonDilutiveFinancingAgreementHSBCFranceMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Dilutive Financing Agreement, HSBC France", "verboseLabel": "HSBC \"PGE\"", "label": "Non-Dilutive Financing Agreement, HSBC France [Member]", "documentation": "Non-Dilutive Financing Agreement, HSBC France" } } }, "auth_ref": [] }, "nbx_NonExecutiveMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonExecutiveMember", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-executive", "label": "Non-executive [Member]", "documentation": "Non-executive" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r460" ] }, "nbx_NonManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NonManagementMember", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-management", "label": "Non-management [Member]", "documentation": "Non-management" } } }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r423", "r434", "r444", "r468", "r477" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r451" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r450" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r468" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r488" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r488" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [axis]", "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r205" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [domain]", "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r205" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r85", "r309", "r351" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofRefundLiabilitiesDetails": { "parentTag": "ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities", "weight": 1.0, "order": 1.0 } }, "lang": { "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofRefundLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "lang": { "en": { "role": { "documentation": "The amount of non-current deferred income including non-current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r548", "r551" ] }, "ifrs-full_NoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets", "periodStartLabel": "Non-current financial assets at beginning of period", "periodEndLabel": "Non-current financial assets at end of period", "label": "Non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_NoncurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial liabilities", "verboseLabel": "Of which Non-Current", "label": "Non-current financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r87", "r310", "r351" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisions", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current provisions", "label": "Non-current provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_NoncurrentRefundsProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentRefundsProvision", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofRefundLiabilitiesDetails": { "parentTag": "ifrs-full_RefundsProvision", "weight": 1.0, "order": 2.0 }, "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current refund liabilities", "label": "Non-current refunds provision" } }, "en": { "role": { "documentation": "The amount of non-current provision for refunds. [Refer: Refunds provision]" } } }, "auth_ref": [ "r336", "r337" ] }, "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Non-derivative financial liabilities, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities." } } }, "auth_ref": [ "r152", "r277" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less than 1\u00a0year", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r105", "r106", "r115", "r186", "r189", "r306", "r364", "r375" ] }, "ifrs-full_NotLaterThanThreeMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanThreeMonthsMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due in 3 months or less", "label": "Not later than three months [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } } }, "auth_ref": [ "r545" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r545" ] }, "nbx_NotionalAmountOfDerivativeFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NotionalAmountOfDerivativeFinancialInstruments", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount of derivative financial instruments", "label": "Notional Amount Of Derivative Financial Instruments", "documentation": "Notional Amount Of Derivative Financial Instruments" } } }, "auth_ref": [] }, "nbx_NotionalAmountOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NotionalAmountOfDerivatives", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Notional Amount Of Derivatives", "documentation": "Notional Amount Of Derivatives" } } }, "auth_ref": [] }, "nbx_NumberOfAwardsExercisedInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NumberOfAwardsExercisedInShareBasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of awards, exercised (in shares)", "verboseLabel": "Number of options, exercised (in shares)", "label": "Number Of Awards Exercised In Share-based Payment Arrangement", "documentation": "Number Of Awards Exercised In Share-based Payment Arrangement" } } }, "auth_ref": [] }, "nbx_NumberOfAwardsForfeitedInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NumberOfAwardsForfeitedInShareBasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of awards lapsed or cancelled (in shares)", "verboseLabel": "Number of options lapsed or cancelled (in shares)", "label": "Number Of Awards Forfeited In Share-based Payment Arrangement", "documentation": "Number Of Awards Forfeited In Share-based Payment Arrangement" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofPayrollCostsDetails", "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "End of period headcount) (employee)", "label": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r545" ] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued (in shares)", "verboseLabel": "Number of awards issued (in shares)", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r129", "r538" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issuable (in shares)", "label": "Number of other equity instruments exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r538" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "verboseLabel": "Awards exercised during the period (in shares)", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r538" ] }, "nbx_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementIncludingSharesLapsedOrCancelledDuringThePeriod": { "xbrltype": "sharesItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementIncludingSharesLapsedOrCancelledDuringThePeriod", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of awards lapsed or cancelled during the period (in shares)", "label": "Number of Other Equity Instruments Forfeited in Share-based Payment Arrangement Including Shares Lapsed or Cancelled During the Period", "documentation": "Number of Other Equity Instruments Forfeited in Share-based Payment Arrangement Including Shares Lapsed or Cancelled During the Period" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "terseLabel": "Number of awards lapsed or cancelled during the period (in shares)", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r538" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in shares)", "periodEndLabel": "Outstanding, end of period (in shares)", "terseLabel": "Number of awards outstanding (in shares)", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r538" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in shares)", "periodEndLabel": "Outstanding at end of period (in shares)", "terseLabel": "Number of share options outstanding in share-based payment arrangement (in shares)", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r118", "r122", "r125", "r251", "r255" ] }, "nbx_NumberOfParentEntities": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NumberOfParentEntities", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of parent entities", "label": "Number Of Parent Entities", "documentation": "Number Of Parent Entities" } } }, "auth_ref": [] }, "nbx_NumberOfPatientsInClinicalTrial": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NumberOfPatientsInClinicalTrial", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patients", "label": "Number Of Patients In Clinical Trial", "documentation": "Number Of Patients In Clinical Trial" } } }, "auth_ref": [] }, "ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented", "presentation": [ "http://nanobiotix.com/role/LosspershareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of potential ordinary shares that are antidilutive in period presented (in shares)", "label": "Number of potential ordinary shares that are antidilutive in period presented" } }, "en": { "role": { "documentation": "Number of potential ordinary shares that are antidilutive in the period presented." } } }, "auth_ref": [ "r523" ] }, "nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of preceding trading days taken into account in the determination of the share price on the grant date", "label": "Number Of Preceding Trading Days Taken Into Account In The Determination Of The Share Price On The Grant Date", "documentation": "Number Of Preceding Trading Days Taken Into Account In The Determination Of The Share Price On The Grant Date" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issuable (in shares)", "label": "Number of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r123", "r256" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Number of options as of including options exercised during the period (in shares)", "label": "Number of share options exercised in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r121", "r254" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r120", "r253" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued (in shares)", "verboseLabel": "Number of options granted (in shares)", "label": "Number of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r119", "r252" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Capital increase (in shares)", "terseLabel": "Capital increase, net (in shares)", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r543" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "http://nanobiotix.com/role/SharecapitalTreasurySharesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares outstanding at beginning of period (in shares)", "periodEndLabel": "Number of shares outstanding at end of period (in shares)", "terseLabel": "Number of shares outstanding (in shares)", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r195", "r283", "r315" ] }, "nbx_NumberOfShortTermLeaseContracts": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NumberOfShortTermLeaseContracts", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of short term leases", "label": "Number Of Short Term Lease Contracts", "documentation": "Number Of Short Term Lease Contracts" } } }, "auth_ref": [] }, "nbx_NumberOfSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NumberOfSubsidiaries", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of subsidiaries", "label": "Number Of Subsidiaries", "documentation": "Number Of Subsidiaries" } } }, "auth_ref": [] }, "nbx_NumberOfTranchesBorrowings": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "NumberOfTranchesBorrowings", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tranches", "label": "Number Of Tranches, Borrowings", "documentation": "Number Of Tranches, Borrowings" } } }, "auth_ref": [] }, "nbx_OSA20161Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA20161Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2016-1", "label": "OSA 2016-1 [Member]", "documentation": "OSA 2016-1" } } }, "auth_ref": [] }, "nbx_OSA20161OrdinaryMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA20161OrdinaryMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2016 O", "label": "OSA 2016-1 Ordinary [Member]", "documentation": "OSA 2016-1 Ordinary" } } }, "auth_ref": [] }, "nbx_OSA20161PerformanceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA20161PerformanceMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2016-1 P", "label": "OSA 2016-1 Performance [Member]", "documentation": "OSA 2016-1 Performance" } } }, "auth_ref": [] }, "nbx_OSA20162Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA20162Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2016-2", "label": "OSA 2016-2 [Member]", "documentation": "OSA 2016-2" } } }, "auth_ref": [] }, "nbx_OSA2017Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA2017Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2017", "label": "OSA 2017 [Member]", "documentation": "OSA 2017" } } }, "auth_ref": [] }, "nbx_OSA2017OrdinaryMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA2017OrdinaryMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2017 O", "label": "OSA 2017 Ordinary [Member]", "documentation": "OSA 2017 Ordinary" } } }, "auth_ref": [] }, "nbx_OSA2017PerformanceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA2017PerformanceMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2017 P", "label": "OSA 2017 Performance [Member]", "documentation": "OSA 2017 Performance" } } }, "auth_ref": [] }, "nbx_OSA2018Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA2018Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2018", "label": "OSA 2018 [Member]", "documentation": "OSA 2018" } } }, "auth_ref": [] }, "nbx_OSA20191Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA20191Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2019-1", "label": "OSA 2019-1 [Member]", "documentation": "OSA 2019-1" } } }, "auth_ref": [] }, "nbx_OSA2020Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA2020Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2020", "label": "OSA 2020 [Member]", "documentation": "OSA 2020" } } }, "auth_ref": [] }, "nbx_OSA202104Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202104Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2021-04", "label": "OSA 2021-04 [Member]", "documentation": "OSA 2021-04" } } }, "auth_ref": [] }, "nbx_OSA202104OrdinaryMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202104OrdinaryMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2021-04 O", "label": "OSA 2021-04 Ordinary [Member]", "documentation": "OSA 2021-04 Ordinary" } } }, "auth_ref": [] }, "nbx_OSA202104PMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202104PMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2021-04 P", "label": "OSA 2021-04 P [Member]", "documentation": "OSA 2021-04 P" } } }, "auth_ref": [] }, "nbx_OSA202104PerformanceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202104PerformanceMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2021-04 P", "label": "OSA 2021-04 Performance [Member]", "documentation": "OSA 2021-04 Performance" } } }, "auth_ref": [] }, "nbx_OSA202106Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202106Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2021-06", "label": "OSA 2021-06 [Member]", "documentation": "OSA 2021-06" } } }, "auth_ref": [] }, "nbx_OSA202106OAndOSA202106Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202106OAndOSA202106Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2021 06 O and OSA 2021 06", "label": "OSA 2021 06 O and OSA 2021 06 [Member]", "documentation": "OSA 2021 06 O and OSA 2021 06" } } }, "auth_ref": [] }, "nbx_OSA202106OrdinaryMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202106OrdinaryMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2021-06 O", "label": "OSA 2021-06 Ordinary [Member]", "documentation": "OSA 2021-06 Ordinary" } } }, "auth_ref": [] }, "nbx_OSA202106PMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202106PMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2021-06 P", "label": "OSA 2021-06 P [Member]", "documentation": "OSA 2021-06 P" } } }, "auth_ref": [] }, "nbx_OSA202106PerformanceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202106PerformanceMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2021-06 P", "label": "OSA 2021-06 Performance [Member]", "documentation": "OSA 2021-06 Performance" } } }, "auth_ref": [] }, "nbx_OSA202206Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202206Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2022-06", "label": "OSA 2022-06 [Member]", "documentation": "OSA 2022-06" } } }, "auth_ref": [] }, "nbx_OSA202206OMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202206OMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2022-06 O", "label": "OSA 2022-06 O [Member]", "documentation": "OSA 2022-06 O" } } }, "auth_ref": [] }, "nbx_OSA202206OrdinaryMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202206OrdinaryMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2022-06 O", "label": "OSA 2022-06 Ordinary [Member]", "documentation": "OSA 2022-06 Ordinary" } } }, "auth_ref": [] }, "nbx_OSA202206PMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202206PMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2022-06 P", "label": "OSA 2022-06 P [Member]", "documentation": "OSA 2022-06 P" } } }, "auth_ref": [] }, "nbx_OSA202301Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202301Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2023-01", "label": "OSA 2023-01 [Member]", "documentation": "OSA 2023-01 Member" } } }, "auth_ref": [] }, "nbx_OSA202301OMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202301OMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2023 - 01", "label": "OSA 2023 - 01 O [Member]", "documentation": "OSA 2023 - 01 O Member" } } }, "auth_ref": [] }, "nbx_OSA202301OrdinaryMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202301OrdinaryMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2023-01 O", "label": "OSA 2023-01 Ordinary [Member]", "documentation": "OSA 2023-01 Ordinary Member" } } }, "auth_ref": [] }, "nbx_OSA202401Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202401Member", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2024-01", "label": "OSA 2024-01 [Member]", "documentation": "OSA 2024-01" } } }, "auth_ref": [] }, "nbx_OSA202401OMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202401OMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2024 - 01 O", "label": "OSA 2024 - 01 O [Member]", "documentation": "OSA 2024 - 01 O" } } }, "auth_ref": [] }, "nbx_OSA202401OrdinaryMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202401OrdinaryMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2024-01 Ordinary", "label": "OSA 2024-01 Ordinary [Member]", "documentation": "OSA 2024-01 Ordinary" } } }, "auth_ref": [] }, "nbx_OSA202501Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202501Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2025-01", "label": "OSA 2025-01 [Member]", "documentation": "OSA 2025-01" } } }, "auth_ref": [] }, "nbx_OSA202502Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSA202502Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA 2025-02", "label": "OSA 2025-02 [Member]", "documentation": "OSA 2025-02" } } }, "auth_ref": [] }, "nbx_OSABSPCEMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSABSPCEMember", "presentation": [ "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA & BSPCE", "label": "OSA & BSPCE [Member]", "documentation": "OSA & BSPCE" } } }, "auth_ref": [] }, "nbx_OSALLY2019Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSALLY2019Member", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA LLY 2019", "label": "OSA LLY 2019 [Member]", "documentation": "OSA LLY 2019" } } }, "auth_ref": [] }, "nbx_OSAMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OSAMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OSA", "label": "OSA [Member]", "documentation": "OSA" } } }, "auth_ref": [] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office and IT equipment", "label": "Office equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r332" ] }, "nbx_OneMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OneMemberMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Member", "label": "One Member [Member]", "documentation": "One Member" } } }, "auth_ref": [] }, "nbx_OneYearAfterMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OneYearAfterMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1 year after", "label": "One Year After [Member]", "documentation": "One Year After" } } }, "auth_ref": [] }, "nbx_OpenTaxYearAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OpenTaxYearAxis", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Open Tax Year [Axis]", "label": "Open Tax Year [Axis]", "documentation": "Open Tax Year" } } }, "auth_ref": [] }, "nbx_OpenTaxYearDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OpenTaxYearDomain", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Open Tax Year [Domain]", "label": "Open Tax Year [Domain]", "documentation": "Open Tax Year" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating expenses", "label": "Operating expense" } } }, "auth_ref": [ "r552" ] }, "nbx_OptimizationOfCashMangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OptimizationOfCashMangementsMember", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Optimization of Cash Mangements", "label": "Optimization of Cash Mangements [Member]", "documentation": "Optimization of Cash Mangements" } } }, "auth_ref": [] }, "nbx_OptionLifeOtherEquityInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OptionLifeOtherEquityInstrumentsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity (in years)", "label": "Option Life, Other Equity Instruments Granted", "documentation": "Option Life, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non cash income and expenses", "label": "Other adjustments for non-cash items" } } }, "auth_ref": [ "r533" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "label": "Other comprehensive income" } } }, "auth_ref": [ "r90", "r292", "r319", "r326" ] }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains and losses on retirement benefit obligations\u00a0(IAS 19)", "label": "Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r311", "r327", "r514" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustments", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r311", "r326" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedge", "label": "Other comprehensive income, net of tax, gains (losses) on hedging instruments that hedge investments in equity instruments" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on hedging instruments that hedge investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r311", "r326" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains and losses (IAS 19)", "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r311", "r326", "r514" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss) that may be reclassified subsequently to income (loss)", "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r396", "r397" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss) that will not be reclassified subsequently to income (loss)", "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r396", "r397" ] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "totalLabel": "Other current assets", "label": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 }, "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities", "label": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other current receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r388", "r394" ] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other financial expense", "label": "Other finance cost" } } }, "auth_ref": [ "r545" ] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 }, "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "totalLabel": "Other income", "label": "Other income" } } }, "auth_ref": [ "r37", "r390", "r391" ] }, "nbx_OtherMiscellaneousCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OtherMiscellaneousCurrentLiabilities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label": "Other Miscellaneous Current Liabilities", "documentation": "Other Miscellaneous Current Liabilities" } } }, "auth_ref": [] }, "nbx_OtherMiscellaneousIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OtherMiscellaneousIncomeOther", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other operating income", "label": "Other Miscellaneous Income, Other", "documentation": "Other Miscellaneous Income, Other" } } }, "auth_ref": [] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_OperatingExpense", "weight": -1.0, "order": 3.0 }, "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating income and expenses", "totalLabel": "Total Other operating income and expenses", "label": "Other operating income (expense)" } } }, "auth_ref": [ "r552" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r460" ] }, "ifrs-full_OtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherProvisions", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Other provisions at beginning of period", "periodEndLabel": "Other provisions at end of period", "label": "Other provisions" } }, "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r46", "r231", "r286", "r312" ] }, "nbx_OtherProvisionsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OtherProvisionsRollForward", "presentation": [ "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Provisions [Roll Forward]", "label": "Other Provisions [Roll Forward]", "documentation": "Other Provisions" } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Reserve", "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r389", "r395" ] }, "ifrs-full_OtherReservesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReservesMember", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Reserve", "label": "Other reserves [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r197", "r295" ] }, "nbx_OtherSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OtherSalesMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other sales", "label": "Other Sales [Member]", "documentation": "Other Sales" } } }, "auth_ref": [] }, "nbx_OtherServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "OtherServicesMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Services", "label": "Other Services [Member]", "documentation": "Other Services" } } }, "auth_ref": [] }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other permanent differences", "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r3", "r207" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r421", "r432", "r442", "r475" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r424", "r435", "r445", "r478" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r424", "r435", "r445", "r478" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "OwnershipAxis", "presentation": [ "http://nanobiotix.com/role/RelatedpartiesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "OwnershipDomain", "presentation": [ "http://nanobiotix.com/role/RelatedpartiesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PGELoanAgreementBPIFranceAndHSBCFranceMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "PGE Loans", "terseLabel": "HSBC \u201cPGE\u201d", "label": "PGE Loan Agreement, BPI France And HSBC France [Member]", "documentation": "PGE Loan Agreement, BPI France And HSBC France" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Par value per share (euro per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r194", "r282", "r314" ] }, "nbx_PatientThresholdAmount": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PatientThresholdAmount", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails", "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of threshold", "label": "Patient Threshold, Amount", "documentation": "Patient Threshold, Amount" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r449" ] }, "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll tax and other payroll liabilities", "label": "Payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } } }, "auth_ref": [ "r551" ] }, "nbx_PayablesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PayablesTypeAxis", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payables Type [Axis]", "label": "Payables Type [Axis]", "documentation": "Payables Type" } } }, "auth_ref": [] }, "nbx_PayablesTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PayablesTypeDomain", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payables Type [Domain]", "label": "Payables Type [Domain]", "documentation": "Payables Type [Domain]" } } }, "auth_ref": [] }, "nbx_PaymentOfBonuses": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PaymentOfBonuses", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Higher bonus payment amount", "label": "Payment of Bonuses", "documentation": "Payment of Bonuses" } } }, "auth_ref": [] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transaction costs", "label": "Payments for share issue costs" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r531" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_PaymentsToSuppliersForGoodsAndServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsToSuppliersForGoodsAndServices", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to suppliers for goods and services", "label": "Payments to suppliers for goods and services" } }, "en": { "role": { "documentation": "The cash outflow to suppliers for goods and services." } } }, "auth_ref": [ "r341" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r459" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r459" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r451" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r468" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r461" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r450" ] }, "nbx_PercentageAdjustmentDegradationToForwardRate": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PercentageAdjustmentDegradationToForwardRate", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage adjustment degradation to forward rate", "label": "Percentage Adjustment Degradation To Forward Rate", "documentation": "Percentage Adjustment Degradation To Forward Rate" } } }, "auth_ref": [] }, "nbx_PercentageIncreaseDecreaseInPayrollExpense": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PercentageIncreaseDecreaseInPayrollExpense", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in employee benefit expense, percentage", "label": "Percentage Increase (Decrease) In Payroll Expense", "documentation": "Percentage Increase (Decrease) In Payroll Expense" } } }, "auth_ref": [] }, "nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in purchases, sub-contracting and other expenses, percentage", "label": "Percentage Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses", "documentation": "Percentage Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses" } } }, "auth_ref": [] }, "nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PercentageIncreaseDecreaseInRentFeesAndOtherExpenses", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in rent, fees, and other expenses, percentage", "label": "Percentage Increase (Decrease) In Rent, Fees, And Other Expenses", "documentation": "Percentage Increase (Decrease) In Rent, Fees, And Other Expenses" } } }, "auth_ref": [] }, "nbx_PercentageOfHedgedItemToTotalRiskExposure": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PercentageOfHedgedItemToTotalRiskExposure", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of hedged item to total risk exposure", "label": "Percentage Of Hedged Item To Total Risk Exposure", "documentation": "Percentage Of Hedged Item To Total Risk Exposure" } } }, "auth_ref": [] }, "nbx_PeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PeriodAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period [Axis]", "label": "Period [Axis]", "documentation": "Period" } } }, "auth_ref": [] }, "nbx_PeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PeriodDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period [Domain]", "label": "Period [Domain]", "documentation": "Period [Domain]" } } }, "auth_ref": [] }, "nbx_PeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PeriodOneMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period One", "label": "Period One [Member]", "documentation": "Period One" } } }, "auth_ref": [] }, "nbx_PeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PeriodTwoMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period Two", "label": "Period Two [Member]", "documentation": "Period Two" } } }, "auth_ref": [] }, "nbx_PlusTenPercentMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PlusTenPercentMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales +10%", "label": "Plus Ten Percent [Member]", "documentation": "Plus Ten Percent" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r452" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r508" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r451" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofCommitmentsforRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense for the period", "label": "Post-employment benefit expense in profit or loss, defined benefit plans" } } }, "auth_ref": [ "r514", "r519" ] }, "nbx_PrepaymentsOnTangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PrepaymentsOnTangibleAssetsMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments on tangible assets", "label": "Prepayments On Tangible Assets [Member]", "documentation": "Prepayments On Tangible Assets" } } }, "auth_ref": [] }, "nbx_PrincipalAndFixedRateMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "PrincipalAndFixedRateMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal and Fixed Rate", "label": "Principal And Fixed Rate [Member]", "documentation": "Principal And Fixed Rate" } } }, "auth_ref": [] }, "nbx_ProceedsDueFromCollaborationAgreementsMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProceedsDueFromCollaborationAgreementsMilestonePayment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds receivable due to milestone completion", "label": "Proceeds Due From Collaboration Agreements, Milestone Payment", "documentation": "Proceeds Due From Collaboration Agreements, Milestone Payment" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in loans - Royalty Financing", "verboseLabel": "Proceeds from borrowings", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r343" ] }, "nbx_ProceedsFromContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProceedsFromContractLiabilities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from contract liabilities", "label": "Proceeds From Contract Liabilities", "documentation": "Proceeds From Contract Liabilities" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromCurrentBorrowings", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from current borrowings", "label": "Proceeds from current borrowings" } }, "en": { "role": { "documentation": "The cash inflow from current borrowings obtained. [Refer: Current borrowings]" } } }, "auth_ref": [ "r531" ] }, "nbx_ProceedsFromIncomeTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProceedsFromIncomeTaxCredit", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Refund of research tax credit", "label": "Proceeds From Income Tax Credit", "documentation": "Proceeds From Income Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increases", "label": "Proceeds from issue of ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r531" ] }, "nbx_ProceedsFromLoansAndConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProceedsFromLoansAndConditionalAdvances", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in other loans and conditional advances", "label": "Proceeds From Loans And Conditional Advances", "documentation": "Proceeds From Loans And Conditional Advances" } } }, "auth_ref": [] }, "nbx_ProceedsFromMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProceedsFromMilestonePayment", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from milestone payment", "label": "Proceeds From Milestone Payment", "documentation": "Proceeds From Milestone Payment" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductOrServiceAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and services [axis]", "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r175", "r354", "r379" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductsAndServicesDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesDomain", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and services", "label": "Products and services [domain]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r175", "r354", "r379" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 }, "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVEINCOMELOSS", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss for the period", "terseLabel": "Net income (loss) for the period", "verboseLabel": "Net loss for the period", "negatedLabel": "Net losses", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r79", "r81", "r169", "r171", "r230", "r250", "r291", "r318", "r351", "r356" ] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss for the period (in thousands of euros)", "label": "Profit (loss), attributable to owners of parent" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r321" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Profit (loss) before tax" } } }, "auth_ref": [ "r132", "r377", "r378", "r390", "r391" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "label": "Profit (loss) from operating activities" } } }, "auth_ref": [ "r334", "r552" ] }, "nbx_ProjectAxisAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProjectAxisAxis", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Project Axis [Axis]", "label": "Project Axis [Axis]", "documentation": "Project Axis" } } }, "auth_ref": [] }, "nbx_ProjectAxisDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProjectAxisDomain", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Project Axis [Domain]", "label": "Project Axis [Domain]", "documentation": "Project Axis [Domain]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "periodStartLabel": "Property, plant and equipment at beginning of period", "periodEndLabel": "Property, plant and equipment at end of period", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r14", "r216", "r299" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment [member]", "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r15", "r217", "r335", "r355", "r380", "r382" ] }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInAssociate", "presentation": [ "http://nanobiotix.com/role/RelatedpartiesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proportion of ownership interest in associate", "label": "Proportion of ownership interest in associate" } }, "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r39", "r40", "r82" ] }, "nbx_ProvisionForRetirementBenefitObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProvisionForRetirementBenefitObligations", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails": { "parentTag": "nbx_ProvisionForRetirementBenefitObligationsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Provision for retirement benefit obligations\u00a0(IAS 19)", "label": "Provision for Retirement Benefit Obligations", "documentation": "Provision for Retirement Benefit Obligations" } } }, "auth_ref": [] }, "nbx_ProvisionForRetirementBenefitObligationsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProvisionForRetirementBenefitObligationsNet", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails": { "parentTag": "nbx_DepreciationAmortizationAndProvisionExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total Provision for retirement benefit obligations\u00a0(IAS 19)", "label": "Provision for retirement benefit obligations\u00a0Net", "documentation": "Provision for retirement benefit obligations\u00a0Net" } } }, "auth_ref": [] }, "nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProvisionUsedAndUnusedProvisionReversedOtherProvisions", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails", "http://nanobiotix.com/role/RetirementobligationsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decreases", "verboseLabel": "Decreases", "label": "Provision Used And Unused Provision Reversed, Other Provisions", "documentation": "Provision Used And Unused Provision Reversed, Other Provisions" } } }, "auth_ref": [] }, "ifrs-full_ProvisionUsedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProvisionUsedOtherProvisions", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails", "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision used", "verboseLabel": "Reversal of provision for disputes and charges", "label": "Provision used, other provisions" } }, "en": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r48", "r233" ] }, "ifrs-full_ProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProvisionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Provisions [abstract]", "label": "Provisions [abstract]" } } }, "auth_ref": [] }, "nbx_ProvisionsAbstractAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProvisionsAbstractAbstract", "lang": { "en-us": { "role": { "label": "ProvisionsAbstract [Abstract]", "documentation": "ProvisionsAbstract [Abstract]" } } }, "auth_ref": [] }, "nbx_ProvisionsForChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProvisionsForChargesMember", "presentation": [ "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails", "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions for charges", "label": "Provisions For Charges [Member]", "documentation": "Provisions For Charges" } } }, "auth_ref": [] }, "nbx_ProvisionsForDisputesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ProvisionsForDisputesMember", "presentation": [ "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails", "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions for disputes", "label": "Provisions For Disputes [Member]", "documentation": "Provisions For Disputes" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of intangible assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "(Increase) / Decrease in non-current financial assets", "label": "Purchase of other long-term assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_PurchasedCallOptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchasedCallOptionsMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchased call options", "label": "Purchased call options [member]" } }, "en": { "role": { "documentation": "This member stands for derivative financial contracts purchased that give the entity the right, but not the obligation, to purchase an underlying asset at a specified strike price. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r367", "r376" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r449" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r449" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r73", "r97", "r109", "r125", "r201", "r352", "r353", "r540" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range", "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r73", "r97", "r109", "r125", "r201", "r352", "r353", "r540" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [member]", "verboseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReceiptsFromSalesOfGoodsAndRenderingOfServices", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receipts from sales of goods and rendering of services", "label": "Receipts from sales of goods and rendering of services" } }, "en": { "role": { "documentation": "The cash inflow from sales of goods and rendering of services." } } }, "auth_ref": [ "r340" ] }, "ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RecognisedLiabilitiesDefinedBenefitPlan", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit liability", "label": "Net defined benefit liability" } }, "en": { "role": { "documentation": "The amount of deficit in a defined benefit plan. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r548" ] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://nanobiotix.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in intangible assets other than goodwill [abstract]", "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]", "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfNumberOfSharesOutstandingAbstract", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "label": "Reconciliation of number of shares outstanding [abstract]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r416", "r427", "r437", "r470" ] }, "nbx_RecruitingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RecruitingExpense", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term employee benefits accruals", "label": "Recruiting Expense", "documentation": "Recruiting Expense" } } }, "auth_ref": [] }, "ifrs-full_RefundsProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RefundsProvision", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofRefundLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Refund liabilities", "terseLabel": "Refund liabilities", "label": "Refunds provision" } }, "en": { "role": { "documentation": "The amount of provision for refunds to be made by the entity to its customers. [Refer: Other provisions]" } } }, "auth_ref": [ "r336", "r337" ] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related party transactions [abstract]", "label": "Related party transactions [abstract]" } } }, "auth_ref": [] }, "nbx_RepaymentOfConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RepaymentOfConsiderationAmount", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of consideration amount", "label": "Repayment Of Consideration Amount", "documentation": "Repayment Of Consideration Amount" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loan repayments", "terseLabel": "Loans repayments", "label": "Repayments of borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r344" ] }, "ifrs-full_RepaymentsOfCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfCurrentBorrowings", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of current borrowings", "label": "Repayments of current borrowings" } }, "en": { "role": { "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]" } } }, "auth_ref": [ "r531" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 }, "http://nanobiotix.com/role/OperatingexpensesDisclosureofResearchandDevelopmentExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails", "http://nanobiotix.com/role/OperatingexpensesDisclosureofResearchandDevelopmentExpenseDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research and development expenses", "terseLabel": "Research and development expense", "negatedTotalLabel": "Research and development expenses", "label": "Research and development expense" } } }, "auth_ref": [ "r59", "r243" ] }, "nbx_ResearchAndDevelopmentExpense1Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ResearchAndDevelopmentExpense1Member", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails", "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D", "label": "Research And Development Expense 1 [Member]", "documentation": "Research And Development Expense 1" } } }, "auth_ref": [] }, "nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofResearchandDevelopmentExpenseDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofResearchandDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation, amortization and provision expenses", "label": "Research And Development Expense, Depreciation, Amortization And Provision Expense", "documentation": "Research And Development Expense, Depreciation, Amortization And Provision Expense" } } }, "auth_ref": [] }, "nbx_ResearchAndDevelopmentExpensePayrollCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ResearchAndDevelopmentExpensePayrollCosts", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofResearchandDevelopmentExpenseDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofResearchandDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payroll costs (including share-based payments)", "label": "Research And Development Expense, Payroll Costs", "documentation": "Research And Development Expense, Payroll Costs" } } }, "auth_ref": [] }, "nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofResearchandDevelopmentExpenseDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofResearchandDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases, sub-contracting and other expenses", "label": "Research And Development Expense, Sub-Contracting And Other Expenses", "documentation": "Research And Development Expense, Sub-Contracting And Other Expenses" } } }, "auth_ref": [] }, "nbx_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research And Development [Member]", "documentation": "Research And Development" } } }, "auth_ref": [] }, "nbx_ResearchAndDevelopmentTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ResearchAndDevelopmentTaxCredit", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit", "label": "Research And Development, Tax Credit", "documentation": "Research And Development, Tax Credit" } } }, "auth_ref": [] }, "nbx_ResearchOrganizationCROAndToClinicalServicesProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ResearchOrganizationCROAndToClinicalServicesProvidersMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier", "label": "Research Organization (CRO) and to Clinical Services Providers [Member]", "documentation": "Research Organization (CRO) and to Clinical Services Providers" } } }, "auth_ref": [] }, "nbx_ResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ResearchTaxCredit", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit", "label": "Research Tax Credit", "documentation": "Research Tax Credit" } } }, "auth_ref": [] }, "nbx_ResearchTaxCreditUtilizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ResearchTaxCreditUtilizationPeriod", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit utilization period", "label": "Research Tax Credit Utilization Period", "documentation": "Research Tax Credit Utilization Period" } } }, "auth_ref": [] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RestatementAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r417", "r428", "r438", "r471" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r418", "r429", "r439", "r472" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r425", "r436", "r446", "r479" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RestatementDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated deficit", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r389", "r395", "r397" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss for the period", "negatedTerseLabel": "Net loss for the period", "label": "Retained earnings, profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r550" ] }, "nbx_RetirementObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RetirementObligationAbstract", "lang": { "en-us": { "role": { "label": "Retirement Obligation [Abstract]", "documentation": "Retirement Obligation" } } }, "auth_ref": [] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues and other income", "terseLabel": "Total revenues and other income", "label": "Revenue" } } }, "auth_ref": [ "r89", "r132", "r167", "r170", "r175", "r176", "r177", "r322", "r351", "r390", "r391" ] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAbstract", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues and other income", "label": "Revenue [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from contracts with customers" } } }, "auth_ref": [ "r99", "r100", "r182" ] }, "ifrs-full_RevenueFromGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromGovernmentGrants", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidies", "label": "Income from government grants" } } }, "auth_ref": [ "r521" ] }, "nbx_RightOfUseBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RightOfUseBuildingsMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use \u2013 Buildings", "label": "Right Of Use, Buildings [Member]", "documentation": "Right Of Use, Buildings" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets [member]", "label": "Right-of-use assets [member]" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r102" ] }, "nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Risk Free Interest Rate, Other Equity Instruments Granted", "documentation": "Risk Free Interest Rate, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "nbx_RiskNotHedgedMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RiskNotHedgedMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk Not Hedged", "label": "Risk Not Hedged [Member]", "documentation": "Risk Not Hedged" } } }, "auth_ref": [] }, "nbx_RoyaltiesAgreementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RoyaltiesAgreementPeriod", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties agreement, period", "label": "Royalties Agreement, Period", "documentation": "Royalties Agreement, Period" } } }, "auth_ref": [] }, "nbx_RoyaltyFinancingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RoyaltyFinancingAgreementMember", "presentation": [ "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Financing Agreement", "label": "Royalty Financing Agreement [Member]", "documentation": "Royalty Financing Agreement" } } }, "auth_ref": [] }, "nbx_RoyaltyFinancingBondMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RoyaltyFinancingBondMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Financing Bond", "label": "Royalty Financing Bond [Member]", "documentation": "Royalty Financing Bond" } } }, "auth_ref": [] }, "nbx_RoyaltyFinancingBondsHoldersPercentage": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RoyaltyFinancingBondsHoldersPercentage", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty financing bonds holders, percent", "label": "Royalty Financing Bonds Holders Percentage", "documentation": "Royalty Financing Bonds Holders Percentage" } } }, "auth_ref": [] }, "nbx_RoyaltyFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RoyaltyFinancingMember", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinFinancialLiabilitiesDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://nanobiotix.com/role/NetfinancialincomelossDisclosureofNetFinancialIncomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Financing", "label": "Royalty Financing [Member]", "documentation": "Royalty Financing" } } }, "auth_ref": [] }, "nbx_RoyaltyPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "RoyaltyPayables", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected future royalty payments", "label": "Royalty Payables", "documentation": "Royalty Payables" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r488" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r488" ] }, "nbx_SaleOfStockPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SaleOfStockPrice", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock price", "label": "Sale Of Stock Price", "documentation": "Sale Of Stock Price" } } }, "auth_ref": [] }, "nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock", "presentation": [ "http://nanobiotix.com/role/IncometaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of reconciliation between statutory and effective income tax", "label": "Schedule Of Detailed Information About The Reconciliation Between Statutory And Effective Income Tax [Table Text Block]", "documentation": "Schedule Of Detailed Information About The Reconciliation Between Statutory And Effective Income Tax" } } }, "auth_ref": [] }, "nbx_SecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SecondTrancheMember", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Tranche", "label": "Second Tranche [Member]", "documentation": "Second Tranche" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r399" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r401" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "SegmentGeographicalDomain", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 }, "http://nanobiotix.com/role/OperatingexpensesDisclosureofSellingGeneralandAdministrativeExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofSellingGeneralandAdministrativeExpensesDetails", "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Selling, general and administrative expenses", "negatedTotalLabel": "Total SG&A expenses", "label": "Selling, general and administrative expense" } } }, "auth_ref": [ "r552" ] }, "nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofSellingGeneralandAdministrativeExpensesDetails": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofSellingGeneralandAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation, amortization and provision expenses", "label": "Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense", "documentation": "Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense" } } }, "auth_ref": [] }, "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpenseMember", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails", "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails", "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "verboseLabel": "SG&A", "label": "Selling, general and administrative expense [member]" } } }, "auth_ref": [ "r542", "r545" ] }, "nbx_SellingGeneralAndAdministrativeExpensePayrollCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SellingGeneralAndAdministrativeExpensePayrollCosts", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofSellingGeneralandAdministrativeExpensesDetails": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofSellingGeneralandAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payroll costs (including share-based payments)", "label": "Selling General And Administrative Expense, Payroll Costs", "documentation": "Selling General And Administrative Expense, Payroll Costs" } } }, "auth_ref": [] }, "nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/OperatingexpensesDisclosureofSellingGeneralandAdministrativeExpensesDetails": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofSellingGeneralandAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases, fees and other expenses", "label": "Selling General And Administrative Expense, Purchases, Fees And Other Expense", "documentation": "Selling General And Administrative Expense, Purchases, Fees And Other Expense" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInCashAndCashEquivalentsDueToTenPercentDecreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInCashAndCashEquivalentsDueToTenPercentDecreaseInExchangeRate", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in cash and cash equivalents due to a 10% decrease in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Cash and Cash Equivalents Due To Ten Percent Decrease In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Cash and Cash Equivalents Due To Ten Percent Decrease In Exchange Rate" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInCashAndCashEquivalentsDueToTenPercentIncreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInCashAndCashEquivalentsDueToTenPercentIncreaseInExchangeRate", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in cash and cash equivalents due to a 10% increase in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Cash and Cash Equivalents Due To Ten Percent Increase In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Cash and Cash Equivalents Due To Ten Percent Increase In Exchange Rate" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInContractLiabilitiesDueToTenPercentDecreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInContractLiabilitiesDueToTenPercentDecreaseInExchangeRate", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in contract liabilities due to a 10% decrease in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Contract Liabilities Due To Ten Percent Decrease In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Contract Liabilities Due To Ten Percent Decrease In Exchange Rate" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInContractLiabilitiesDueToTenPercentIncreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInContractLiabilitiesDueToTenPercentIncreaseInExchangeRate", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in contract liabilities due to a 10% increase in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Contract Liabilities Due To Ten Percent Increase In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Contract Liabilities Due To Ten Percent Increase In Exchange Rate" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in equity due to a 10% decrease in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Decrease In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Decrease In Exchange Rate" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in equity due to a 10% increase in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Increase In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Increase In Exchange Rate" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInFinancingLiabilityDueToTenPercentDecreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInFinancingLiabilityDueToTenPercentDecreaseInExchangeRate", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in contract assets due to a 10% decrease in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Financing Liability Due To Ten Percent Decrease In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Financing Liability Due To Ten Percent Decrease In Exchange Rate" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in net income due to a 10% decrease in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Decrease In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Decrease In Exchange Rate" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in net income due to a 10% increase in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Increase In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Increase In Exchange Rate" } } }, "auth_ref": [] }, "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInRoyaltyFinanacingDueToTenPercentIncreaseInExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInRoyaltyFinanacingDueToTenPercentIncreaseInExchangeRate", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in contract assets due to a 10% increase in exchange rate", "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Royalty Finanacing Due To Ten Percent Increase In Exchange Rate", "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Royalty Finanacing Due To Ten Percent Increase In Exchange Rate" } } }, "auth_ref": [] }, "nbx_ServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ServicesMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Services", "label": "Services [Member]", "documentation": "Services" } } }, "auth_ref": [] }, "nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of initial plan (in thousands of euros)", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "nbx_ShareBasedCompensationServicePeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ShareBasedCompensationServicePeriod", "presentation": [ "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, service period", "label": "Share-based Compensation, Service Period", "documentation": "Share-based Compensation, Service Period" } } }, "auth_ref": [] }, "nbx_ShareBasedCompensationVestingPeriod": { "xbrltype": "decimalItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ShareBasedCompensationVestingPeriod", "presentation": [ "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation, Vesting Period", "label": "Share-Based Compensation, Vesting Period", "documentation": "Share-Based Compensation, Vesting Period" } } }, "auth_ref": [] }, "nbx_ShareBasedPaymentArrangementStockOptionTerm": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ShareBasedPaymentArrangementStockOptionTerm", "presentation": [ "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum term of options granted for share-based payment arrangement", "label": "Share-Based Payment Arrangement, Stock Option Term", "documentation": "Share-Based Payment Arrangement, Stock Option Term" } } }, "auth_ref": [] }, "nbx_ShareBasedPaymentRollForward": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ShareBasedPaymentRollForward", "presentation": [ "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Payment [Roll Forward]", "label": "Share Based Payment [Roll Forward]", "documentation": "Share Based Payment" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Premiums related to share capital", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r389", "r395" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Premiums related to share capital", "verboseLabel": "Premiums related to share capital", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r295" ] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term bank deposits", "label": "Short-term deposits, classified as cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r537" ] }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsExpense", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term employee benefits expense", "label": "Short-term employee benefits expense" } } }, "auth_ref": [ "r545" ] }, "nbx_SignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]", "documentation": "Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "nbx_SocialChargesRelatedToStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SocialChargesRelatedToStockOptions", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash-Settled Share-Based Payment Taxes", "label": "Social Charges Related To Stock Options", "documentation": "Social Charges Related To Stock Options" } } }, "auth_ref": [] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofPayrollCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payroll taxes", "label": "Social security contributions" } } }, "auth_ref": [ "r520" ] }, "nbx_SponsorshipTransitionPayrollExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SponsorshipTransitionPayrollExpense", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sponsorship transition payroll expense", "label": "Sponsorship Transition Payroll Expense", "documentation": "Sponsorship Transition Payroll Expense" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementGeographicalAxis", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r295" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "General principles, Statement of Compliance and Basis of Presentation", "label": "Statement of IFRS compliance [text block]" } } }, "auth_ref": [ "r296" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r420", "r431", "r441", "r474" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "nbx_StockOptionExercisedPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "StockOptionExercisedPeriod", "presentation": [ "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option exercised period", "label": "Stock Option Exercised Period", "documentation": "Stock Option Exercised Period" } } }, "auth_ref": [] }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "lang": { "en-us": { "role": { "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "auth_ref": [] }, "nbx_SubscriptionAssumingPriceFunded": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SubscriptionAssumingPriceFunded", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription assuming price funded", "label": "Subscription Assuming Price Funded", "documentation": "Subscription Assuming Price Funded" } } }, "auth_ref": [] }, "nbx_SubscriptionPriceIfRepaidAfterPercent": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SubscriptionPriceIfRepaidAfterPercent", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription price if repaid after percent", "label": "Subscription Price If Repaid After Percent", "documentation": "Subscription Price If Repaid After Percent" } } }, "auth_ref": [] }, "nbx_SupervisoryBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SupervisoryBoardMember", "presentation": [ "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supervisory Board", "label": "Supervisory Board [Member]", "documentation": "Supervisory Board" } } }, "auth_ref": [] }, "nbx_SupplyServices": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "SupplyServices", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Services", "label": "Supply Services", "documentation": "Supply Services" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r467" ] }, "nbx_TangibleAssetsInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TangibleAssetsInProgressMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use \u2013 Transport equipment", "label": "Tangible Assets In Progress [Member]", "documentation": "Tangible Assets In Progress" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfRevenuesExemptFromTaxation2011", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-taxable items (CIR)", "label": "Tax effect of revenues exempt from taxation" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to revenues that are exempt from taxation. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r207" ] }, "nbx_TaxEffectOfShareBasedPaymentArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TaxEffectOfShareBasedPaymentArrangements", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment", "label": "Tax Effect Of Share-Based Payment Arrangements", "documentation": "Tax Effect Of Share-Based Payment Arrangements" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfTaxLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfTaxLosses", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized deferred tax on timing differences and tax losses", "label": "Tax effect of tax losses" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r207" ] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Theoretical tax (benefit) expense", "label": "Tax expense (income) at applicable tax rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r3", "r207" ] }, "nbx_TechnologyTransferAndTechnicalMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TechnologyTransferAndTechnicalMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology Transfer and Technical", "label": "Technology Transfer And Technical [Member]", "documentation": "Technology Transfer And Technical" } } }, "auth_ref": [] }, "nbx_TechnologyTransferMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TechnologyTransferMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology transfer", "label": "Technology Transfer [Member]", "documentation": "Technology Transfer" } } }, "auth_ref": [] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]", "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r7", "r211" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [domain]", "label": "Temporary difference, unused tax losses and unused tax credits [domain]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r7", "r211" ] }, "nbx_TerminationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TerminationAgreementMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Agreement", "label": "Termination Agreement [Member]", "documentation": "Termination Agreement" } } }, "auth_ref": [] }, "ifrs-full_TerminationBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TerminationBenefitsExpense", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination benefits expense", "label": "Termination benefits expense" } } }, "auth_ref": [ "r518" ] }, "nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/OperatingexpensesDisclosureofOtherOperatingIncomeExpenseDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination of PharmaEngine License and Collaboration Agreement, NBTXR3", "label": "Termination Of PharmaEngine License And Collaboration Agreement, NBTXR3 [Member]", "documentation": "Termination Of PharmaEngine License And Collaboration Agreement, NBTXR3" } } }, "auth_ref": [] }, "nbx_ThirdPartyServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "ThirdPartyServicesMember", "presentation": [ "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party Services", "label": "Third Party Services [Member]", "documentation": "Third Party Services" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails", "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails", "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Domain]", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/CompanyinformationDetails", "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails", "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails", "http://nanobiotix.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of Range", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r73", "r97", "r109", "r125", "r201", "r352", "r353", "r540" ] }, "nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total financial liabilities", "label": "Total Financial Liabilities Including Trade Payables And Other Payables", "documentation": "Total Financial Liabilities Including Trade Payables And Other Payables" } } }, "auth_ref": [] }, "nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total financial liabilities, at fair value", "label": "Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value", "documentation": "Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value" } } }, "auth_ref": [] }, "nbx_TotalImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TotalImpact", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCommercializationDateSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofCumulatedNetSalesSensitivityAnalysisDetails", "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofImpactonDebtofSigningaDealthatwillGeneratePIKEarlyPaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total impact", "label": "Total Impact", "documentation": "Total Impact" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r459" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r466" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION", "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and other payables", "totalLabel": "Total trade and other payables", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables & other accruals", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r393", "r551" ] }, "nbx_TradeAndOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TradeAndOtherPayablesMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and other payables", "label": "Trade And Other Payables [Member]", "documentation": "Trade And Other Payables" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Trade receivables [member]" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r144", "r149", "r272", "r275", "r363", "r545" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r487" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r489" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://nanobiotix.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "nbx_TrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TrancheFourMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche four", "label": "Tranche Four [Member]", "documentation": "Tranche Four" } } }, "auth_ref": [] }, "nbx_TrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TrancheOneMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche one", "label": "Tranche One [Member]", "documentation": "Tranche One" } } }, "auth_ref": [] }, "nbx_TrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TrancheThreeMember", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche three", "label": "Tranche Three [Member]", "documentation": "Tranche Three" } } }, "auth_ref": [] }, "nbx_TrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TrancheTwoMember", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche two", "label": "Tranche Two [Member]", "documentation": "Tranche Two" } } }, "auth_ref": [] }, "nbx_TranchesAxis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TranchesAxis", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranches [Axis]", "label": "Tranches [Axis]", "documentation": "Tranches" } } }, "auth_ref": [] }, "nbx_TranchesDomain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "TranchesDomain", "presentation": [ "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails", "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranches [Domain]", "label": "Tranches [Domain]", "documentation": "Tranches [Domain]" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r490" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r491" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r491" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r489" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r489" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r492" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r490" ] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "calculation": { "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury shares", "label": "Treasury shares" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r41", "r389", "r395" ] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY", "http://nanobiotix.com/role/SharecapitalTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Treasury shares [member]" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r295" ] }, "ifrs-full_TypesOfHedgesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfHedgesAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of hedges [axis]", "label": "Types of hedges [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r137", "r138", "r139", "r268", "r269", "r270" ] }, "ifrs-full_TypesOfHedgesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfHedgesDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of hedges [domain]", "label": "Types of hedges [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of hedges. It also represents the standard value for the 'Types of hedges' axis if no other member is used." } } }, "auth_ref": [ "r137", "r138", "r139", "r268", "r269", "r270" ] }, "ifrs-full_TypesOfInterestRatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInterestRatesAxis", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates [axis]", "label": "Types of interest rates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r539" ] }, "ifrs-full_TypesOfInterestRatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInterestRatesDomain", "presentation": [ "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates", "label": "Types of interest rates [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r539" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [axis]", "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r28", "r110", "r111", "r112", "r114", "r134", "r142", "r143", "r224" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails", "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [domain]", "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r28", "r110", "r111", "r112", "r114", "r134", "r142", "r143", "r224" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r126", "r258" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails", "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails", "http://nanobiotix.com/role/SharecapitalCapitalIssuedDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails", "http://nanobiotix.com/role/SharecapitalDisclosureofDetailofShareCapitalTransactionsDetails", "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails", "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails", "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements", "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r126", "r258" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "UNITED STATES" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "USD", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails", "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "USD / Euro exchange rate", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "nbx_UnderwritingAgreementIssuanceBasisMaximumDiscount": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "UnderwritingAgreementIssuanceBasisMaximumDiscount", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriting agreement, maximum discount", "label": "Underwriting Agreement, Issuance Basis, Maximum Discount", "documentation": "Underwriting Agreement, Issuance Basis, Maximum Discount" } } }, "auth_ref": [] }, "nbx_UnderwritingAgreementMaximumNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "UnderwritingAgreementMaximumNumberOfSharesIssued", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriting agreement, maximum number of shares issued (in shares)", "label": "Underwriting Agreement, Maximum Number Of Shares Issued", "documentation": "Underwriting Agreement, Maximum Number Of Shares Issued" } } }, "auth_ref": [] }, "nbx_UnderwritingAgreementMaximumPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "UnderwritingAgreementMaximumPeriod", "presentation": [ "http://nanobiotix.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriting agreement, maximum period", "label": "Underwriting Agreement, Maximum Period", "documentation": "Underwriting Agreement, Maximum Period" } } }, "auth_ref": [] }, "ifrs-full_UndrawnBorrowingFacilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UndrawnBorrowingFacilities", "crdr": "credit", "presentation": [ "http://nanobiotix.com/role/SignificanttransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undrawn borrowing facilities", "label": "Undrawn borrowing facilities" } }, "en": { "role": { "documentation": "The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]" } } }, "auth_ref": [ "r348" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r486" ] }, "ifrs-full_UnusedProvisionReversedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedProvisionReversedOtherProvisions", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofDepreciationAmortizationandProvisionExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal of provision for disputes", "label": "Unused provision reversed, other provisions" } }, "en": { "role": { "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r49", "r234" ] }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused tax losses", "label": "Unused tax losses for which no deferred tax asset recognised" } }, "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } } }, "auth_ref": [ "r5", "r209" ] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused Tax Losses", "label": "Unused tax losses [member]" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r7", "r211" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation periods of property, plant and equipment", "label": "Useful life measured as period of time, property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r9", "r212" ] }, "ifrs-full_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "VehiclesMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transport equipment", "label": "Vehicles [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r511" ] }, "nbx_VendorsPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "VendorsPayablesMember", "presentation": [ "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails", "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vendors Payables", "label": "Vendors Payables [Member]", "documentation": "Vendors Payables" } } }, "auth_ref": [] }, "nbx_Vesting1Axis": { "xbrltype": "stringItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "Vesting1Axis", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting1 [Axis]", "documentation": "Vesting1" } } }, "auth_ref": [] }, "nbx_Vesting1Domain": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "Vesting1Domain", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails", "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting1 [Domain]", "documentation": "Vesting1" } } }, "auth_ref": [] }, "nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod", "presentation": [ "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting requirements for share-based payment arrangement, acquisition period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period" } } }, "auth_ref": [] }, "nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted": { "xbrltype": "integerItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted", "presentation": [ "http://nanobiotix.com/role/SharecapitalFounderswarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees with service conditions lifted", "label": "Vesting Requirements For Share-Based Payment Arrangement, Employees With Service Conditions Lifted", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Continued Service Condition Lifted, Number Of Employees" } } }, "auth_ref": [] }, "nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod", "presentation": [ "http://nanobiotix.com/role/SharecapitalFreeSharePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting requirements for share-based payment arrangement, holding period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Holding Period", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Holding Period" } } }, "auth_ref": [] }, "nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPercentage", "presentation": [ "http://nanobiotix.com/role/SharecapitalStockOptionPlansDetails", "http://nanobiotix.com/role/SharecapitalWarrantPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting requirements for share-based payment arrangement, vesting percentage", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r455" ] }, "nbx_WaccanoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "WaccanoMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Waccano", "label": "Waccano [Member]", "documentation": "Waccano" } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "presentation": [ "http://nanobiotix.com/role/OperatingexpensesDisclosureofPayrollCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Wages and salaries", "label": "Wages and salaries" } } }, "auth_ref": [ "r520" ] }, "nbx_WattigniesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "WattigniesMember", "presentation": [ "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wattignies", "label": "Wattignies [Member]", "documentation": "Wattignies" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageDurationOfDefinedBenefitObligation2019", "presentation": [ "http://nanobiotix.com/role/RetirementobligationsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Duration", "label": "Weighted average duration of defined benefit obligation" } }, "en": { "role": { "documentation": "The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r25" ] }, "nbx_WeightedAverageExercisePriceOfDerivativeFinancialInstruments": { "xbrltype": "decimalItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "WeightedAverageExercisePriceOfDerivativeFinancialInstruments", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of derivative financial instruments", "label": "Weighted Average Exercise Price Of Derivative Financial Instruments", "documentation": "Weighted Average Exercise Price Of Derivative Financial Instruments" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Grant price (in euro per share)", "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r538" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (euro per share)", "label": "Weighted average exercise price of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r119", "r252" ] }, "nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://nanobiotix.com/20251231", "localname": "WeightedAverageSharePriceOtherEquityInstrumentsGranted", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in euros)", "label": "Weighted Average Share Price, Other Equity Instruments Granted", "documentation": "Weighted Average Share Price, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "presentation": [ "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in euros)", "label": "Weighted average share price, share options granted" } }, "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } } }, "auth_ref": [ "r127" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r44" ] }, "ifrs-full_WrittenPutOptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WrittenPutOptionsMember", "presentation": [ "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Written put options", "label": "Written put options [member]" } }, "en": { "role": { "documentation": "This member stands for derivative financial contracts sold that oblige the entity to purchase an underlying asset at a specified strike price if the other party exercises the option. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r367", "r376" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r453" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "ab", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_ab&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_b&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_b&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_c&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_d&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "86", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86_a&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "58", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_58&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23A&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "24A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24A&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "24B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24B&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "24C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24C&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K_a&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I_b&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20B&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_b&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_a&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "170", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "184", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_184&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_e&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "204", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_a&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_b&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_a&doctype=Standard", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_b&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_c&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_d&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "259", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259_a&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "259", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_a&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "56", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_56_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "56A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_56A&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_60&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "62", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_62&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "72", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "88", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.49", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard", "URIDate": "2025-03-27" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard", "URIDate": "2025-03-27" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_b&doctype=Standard", "URIDate": "2025-03-27" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard", "URIDate": "2025-03-27" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "90", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_90&doctype=Standard", "URIDate": "2025-03-27" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_b&doctype=Standard", "URIDate": "2025-03-27" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r329": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2025-03-27" }, "r330": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_c&doctype=Standard", "URIDate": "2025-03-27" }, "r331": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2025-03-27" }, "r332": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2025-03-27" }, "r333": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r334": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r335": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r336": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "87", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_87&doctype=Standard", "URIDate": "2025-03-27" }, "r337": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Section": "Example 4 Refunds policy", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex4_TI", "URIDate": "2025-03-27" }, "r338": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2025-03-27" }, "r339": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2025-03-27" }, "r340": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_a&doctype=Standard", "URIDate": "2025-03-27" }, "r341": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_c&doctype=Standard", "URIDate": "2025-03-27" }, "r342": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r343": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r344": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r345": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r346": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2025-03-27" }, "r347": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2025-03-27" }, "r348": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_a&doctype=Standard", "URIDate": "2025-03-27" }, "r349": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r350": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2025-03-27" }, "r351": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r352": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r353": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r354": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r355": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r356": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r357": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r358": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "IE72", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_IE72&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r359": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r360": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I_a&doctype=Standard", "URIDate": "2025-03-27" }, "r361": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I_c&doctype=Standard", "URIDate": "2025-03-27" }, "r362": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I_d&doctype=Standard", "URIDate": "2025-03-27" }, "r363": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r364": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r365": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r366": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r367": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B33&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r368": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r369": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r370": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r371": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r372": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r373": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r374": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r375": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r376": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r377": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r378": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r379": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard", "URIDate": "2025-03-27" }, "r380": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r381": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "191", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_191_f&doctype=Standard", "URIDate": "2025-03-27" }, "r382": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "251", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_251&doctype=Standard", "URIDate": "2025-03-27" }, "r383": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_g&doctype=Standard", "URIDate": "2025-03-27" }, "r384": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r385": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2025-03-27" }, "r386": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r387": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70_d&doctype=Standard", "URIDate": "2025-03-27" }, "r388": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r389": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r390": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r391": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r392": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r393": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r394": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r395": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r396": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard", "URIDate": "2025-03-27" }, "r397": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r398": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r399": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r400": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r403": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r404": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r405": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r406": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r407": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r408": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r409": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r410": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r411": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r412": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r413": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r414": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r415": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r416": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r417": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r418": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r419": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r420": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r421": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r422": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r423": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r424": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2025-03-27" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard", "URIDate": "2025-03-27" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "171", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_171&doctype=Standard", "URIDate": "2025-03-27" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_5&doctype=Standard", "URIDate": "2025-03-27" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2025-03-27" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard", "URIDate": "2025-03-27" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2025-03-27" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard", "URIDate": "2025-03-27" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }